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Abstract 
Background and Aims 
Home Parenteral Nutrition (HPN) has been a major advance in the management of 
patients with gastrointestinal failure.   It demands regular monitoring to ensure 
optimal intake, assess treatment response and minimise complications.   The Scottish 
Home Parenteral Nutrition Managed Clinical Network (MCN) affords the opportunity 
to collect and analyse data about many aspects of HPN.   The Network produced a 
guideline advising three monthly monitoring of biochemistry, micronutrients, 
vitamins, weight and anthropometry.   This study firstly assesses the frequency and 
adequacy of monitoring of these complex patients and investigates any effect of this 
on complication rate.   The second chapter is devoted to the outcome data of this 
geographical population and the comparison of survival figures to other intestinal 
failure (IF) centres.   Lastly, hypermanganesemia is commonly reported during the 
follow up of HPN patients.   Manganese (Mn) is added to parenteral nutrition in a 
multi trace element solution.   Flexibility to alter the dose is limited.   Manganese 
dosing and whole blood level is analysed to assess correlation.   Other blood 
parameters are compared to assess any influence they may have on body manganese 
levels. 
 
Methods 
All patients receiving HPN funded by the NHS (National Health Service) in Scotland 
are known to the MCN via the National Contract for provision of HPN.   Data is 
collected in an MS Access database.   Data was extracted from this and absent 
information sought by personal communication. 
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Results 
Monitoring of HPN patients across Scotland is performed regularly, however, only 
one third of patients met the 100 day standard.   Consequences of this seemed 
negligible with no increase in complication rate of those reviewed less often. 
 
Outcome data is broadly comparable to large UK IF centres.   Overall survival at 5 
years is 77.2%.   Outcome is dependent on primary disease diagnosis with Crohns 
disease and motility disorders having the best figures.   Cause of death for the 
majority of patients (65%) is purely disease related rather than as a complication of 
HPN. 
 
Hypermanganesemia was found in 11 of 12 patients at least once during the study 
period.   Whole blood manganese levels were not related to cumulative manganese 
dose, or blood parameters such as C reactive protein, ferritin or alkaline phosphatase. 
 
Conclusions 
It may be clinically viable and economically sensible to decrease the frequency of 
monitoring in HPN patients without detrimental effect.   Complications are no more 
often found in patients reviewed with less frequency than those seen more often.   A 
tailored approach to follow up and monitoring may be appropriate and is worth 
considering with respect to clinical workload and economic consequence. 
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Survival in our Scottish HPN patient population is comparable to that of tertiary UK 
centres and European equivalents, despite our wide and unselected geographical 
population and the logistical difficulties it presents. 
 
Manganese levels are frequently high in our HPN patients.   As yet, no convincing 
data exists to resolve the relevant clinical, biochemical or environmental factors.   A 
multifactorial solution is anticipated. 
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Aims and Objectives 
The first aim of this thesis is to investigate the monitoring of home parenteral 
nutrition (HPN) patients across an entire geographical population.   All patients are 
monitored according to guidelines set by national nutrition experts.   This study aims 
to determine whether Scottish HPN patients are meeting these targets.   All aspects of 
monitoring will be analysed including routine blood tests, micronutrients and trace 
elements, anthropometry, and weight measurement.   The guidelines are, to date, non-
evidence based and a secondary aim of the study is to determine whether more 
infrequent reviews correlate with more complications warranting hospital admission. 
 
Secondly, survival and outcome is to be analysed from this Scottish HPN population.   
All patients commenced on HPN since 2000 have been prospectively recorded on the 
purpose built HPN MCN data base and seven year follow up is now possible.   This 
study aims to establish whether this population of patients behave in a similar way to 
previously reported groups in terms of survival, prognostic factors and HPN 
dependence. 
 
Lastly, one particular trace element of current interest is manganese (Mn).   Many 
studies have reported a high incidence of hypermanganesemia in HPN patients.   
Causes suggested have included dose of Mn prescribed, deranged liver function, 
intercurrent infection or inflammation, contamination of HPN feed and dietary 
contributions.   This thesis aims to examine the behaviour of Mn in this Scottish 
population with regard to cumulative dose, markers of liver derangement and 
inflammation and dose in the past 7, 14, 21, 28, 56 or 84 days.
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Chapter 1 
Introduction 
1.1 Intestinal Failure 
The term Intestinal Failure (IF) emerged as a clinical entity over 20 years ago and was 
originally defined as ‘the reduction in functioning gut mass below the amount 
necessary for adequate digestion and absorption of food’ (Fleming, Remington 1981).   
A more recent definition states that intestinal failure occurs ‘when there is reduced 
intestinal absorption so that macronutrient and/or water and electrolyte supplements 
are needed to maintain health and/or growth’ (Nightingale 2001b).   This later 
definition allows for those patients who simply require fluid and/or electrolyte 
support.   A third, aetiological definition proposes that intestinal failure ‘results from 
obstruction, dysmotility, surgical resection, congenital defect or disease-associated 
loss of absorption and is characterised by the inability to maintain protein-energy, 
fluid, electrolyte or micronutrient balance’ (O’Keefe, Buchman et al. 2006).   The 
condition can be of varied severity and duration. The acute cases tend to be of short 
duration, requiring artificial nutrition for between two weeks and six months and are 
managed in non-specialised units.   Chronic or permanent IF is much less common 
than the acute version of the disease.   A classification to cover the spectrum of 
pathologies has been devised.   Type 1 intestinal failure is classified as self-limiting 
intestinal failure as occurs following abdominal surgery, necessitating short-term fluid 
or nutritional support, and usually resulting in a complete recovery without 
complication.   Type 2 is intestinal failure in severely ill patients with major resections 
of the bowel and septic, metabolic and nutritional complications requiring 
multidisciplinary intervention with metabolic and nutritional support to permit 
recovery.   Type 3 is chronic intestinal failure requiring long-term nutritional support. 
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1.2 Aetiology of Intestinal Failure 
Type 1 failure is a temporary consequence of abdominal surgery or other acute illness.   
Types 2 and 3 can result from a range of conditions affecting the gastrointestinal tract.   
The main causes have not changed since the 1980s when the two main intestinal 
failure units in the UK were set up.   Crohns disease is the most common underlying 
condition, followed by bowel ischaemia, motility disorders, malignancy and radiation 
enteritis.   Post-surgical conditions such as intestinal fistula and chronic adhesive 
obstruction also feature, along with many rarer conditions (Irving 2000). 
 
1.3 Home Parenteral Nutrition 
The provision of Home Parenteral Nutrition (HPN) allows a release from the hospital 
environment for those patients unable to gain nutritional independence with adequate 
gastrointestinal function.   It is a low volume – high cost life preserving treatment for 
patients with intestinal failure (IF), when neither oral nor enteral feeding is effective.   
It can be short term, to facilitate other treatments such as chemotherapy, medium 
term, with the intention of encouraging an adaptive response in those with short bowel 
syndrome (SBS) or whilst awaiting surgery, or long term in patients for whom 
absorptive capacity will never return. 
 
1.4 Indications for Home Parenteral Nutrition 
Short bowel syndrome is the best known form of IF.   A comparison of indications for 
HPN was made between 2000 and 2006 British Artificial Nutrition Survey (BANS) 
data.  Short bowel syndrome (SBS) remained the major reason for requiring HPN, 
although no information was given regarding the length of small bowel remaining or 
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the presence of the colon in continuity.   One group in which numbers of HPN 
patients rose was those termed ‘other diagnoses’.   This comprised a heterogeneous 
group of patients with mainly surgical complications.   Cancer as the main diagnosis 
remained steady at 17% of new cases (Jones 2007). 
 
1.5 Short bowel syndrome (SBS) 
SBS usually results from repeated resection of small bowel strictures due to Crohns 
disease but can also result from extensive small bowel resection as a consequence of 
superior mesenteric artery/vein thrombosis or volvulus (Lal, Teubner et al. 2006; 
Irving 2000).   However, a report from one IF unit demonstrated that the SBS in 
Crohns disease is more often a result of massive resection of inflamed and obstructed 
bowel secondary to peritonitis caused by anastomotic leakage than the pathology itself 
(Irving 2000). 
 
Patients with less than 200cm of functional small bowel are generally said to have 
Short Bowel Syndrome.   However, it is often more accurately defined by the 
proportion of bowel remaining and its functional capacity.   Normal small bowel can 
vary in length between 300cm and 850cm and tends to be shorter in women.   
Congenital cases of SBS have been reported and many patients with a short bowel 
actually start off with a comparatively short length of intestine before resection.   The 
degree of reliance on HPN depends on the absolute length and type of small bowel 
remaining.   Children with less than 30cm of small intestine are unlikely to survive 
without long-term parenteral nutrition.   Causes of SBS differ to those of the adult 
population.   In neonates and infants, the most common causes are necrotising 
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enterocolitits, multiple small bowel atresias, aganglionosis and gastroschisis.   Mid 
gut volvulus is common in older children. 
 
1.6 Small bowel physiology 
The anatomy of the remaining bowel is important in determining the consequences of 
a small bowel resection.   Jejunal resections are better tolerated than ileal resections 
due to the remaining ileal mucosa possessing tight intercellular junctions, which allow 
concentration of its content.   Transit times are also slower in the ileum, as a 
consequence of the narrower diameter, allowing more time for absorption.   Following 
a small bowel resection, ileum is able to structurally and functionally adapt to boost 
its function.   Jejunum can only adapt if anastomosed to functioning colon.   Patients 
with an end jejunostomy show no form of adaptation.   The three main types of patient 
with short bowel include those with jejunal-colonic anastomosis, those with a 
jejunostomy and those with jejunal-ileal anastomosis.   All behave differently with 
respect to their need for fluid and nutritional support, physiological changes following 
surgery and gastric emptying (Nightingale 2001c). 
 
1.7 Other reasons for HPN 
Other patients have intact but non-functioning guts.   Chronic motility disorders are 
rare causes of intestinal failure.   Total enterectomy gives symptomatic relief from 
abdominal distension, vomiting and intermittent bacteraemia but results in type 3 IF, 
with a lifelong dependence on parenteral nutrition. 
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1.8 Epidemiology 
In Europe, Denmark is among the countries with the longest experience of HPN use in 
patients with intestinal failure.   A five-year longitudinal study of HPN patients from 
1996 to 2000 showed that 202 patients were treated during that time period, 34% had 
short bowel syndrome secondary to inflammatory bowel disease, 26% had cancer, 
22% had surgical complications and 19% required parenteral nutrition for other 
reasons.   At the end of 2000, Denmark had a HPN prevalence of 19.2 per million and 
an average annual incidence of five patients per million per year over the studied 
period.   Data on numbers of HPN patients in the UK has been collected since the 
very first patients initiated on the treatment in St Marks Hospital, London and Hope 
Hospital, Salford in 1978.   Since 1995, this has been logged centrally by the British 
Artificial Nutrition Survey (BANS), a constituent committee of the British 
Association of Parenteral and Enteral Nutrition (BAPEN) (Jones 2003).   Each annual 
report has identified an increasing number of HPN patients.   The most recent figures 
available, for 2006, suggest that numbers of new registrations remain static at about 
100 per year (1.7/million population) whereas point (12/million) and period 
(12.5/million) prevalence continue to rise linearly.   In 2006, there were 746 patients 
registered as receiving HPN in the UK.   The number of centres providing treatment 
has decreased yet both point and period prevalence have risen, inferring new cases 
may be concentrating around larger centres (Jones 2007).   From the most recent data 
available, it is clear that some centres are caring for very few patients.   The two 
national IF centres have only 38% of new registrations since 2000.   Concern exists as 
to whether these figures may have implications for quality of care of the patients in 
the longer term (BANS ). 
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In Scotland, there were 11 new HPN registrations in 2006, a similar figure to previous 
years, however, as with the overall UK data, both point (85 patients) and period 
(16.7/million) prevalence have risen linearly since 2001 (Jones 2007). 
 
The most recent European-wide data available for comparison gives point prevalences 
from 2002. (Table 1.1) (Wengler, Micklewright et al. 2006).    The incidence and 
prevalence of HPN varies across Europe reflecting different organisational structures 
and treatment strategies (Staun, Pironi et al. 2009).   Cancer is the predominant 
indication for HPN in the USA and Europe as a whole, but is the least common in the 
UK, Ireland and Denmark; in the UK, Crohn’s Disease is the commonest indication 
for HPN (Jones 2001). 
 
Table 1.1 European HPN registration point prevalence 2002 
Country Point Prevalence in December 2002 
France 186 
Belgium 48 
Italy 112 
Poland 182 
Denmark 132 
Spain 18 
Germany 41 
 
In the UK, the commonest age range for new patients on HPN is 41-60 years; 
accounting for 50% of the new HPN patients (Elia, Russell et al. 2001).   More 
recently, an upward trend in older patients (71-90 years) represent 14.1% of new 
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registrations.   Point prevalence in this group is just under 7%; inferring survival rate 
in this group is not good (Jones 2003), however when the advanced age of these 
patients is considered, perhaps it is inappropriate to compare survival as an outcome. 
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1.9 Initiation of HPN 
Historically, HPN was first attempted soon after in-patient parenteral feeding began in 
the late 1960s.   The multi-bottle systems of feed were impractical, but by the mid 
eighties ‘All-in-one’ solutions were widely used, allowing patients to return to normal 
activities including work and travel.   Since then, the focus has turned to improving 
venous access, identifying and preventing complications, increasing awareness of the 
treatment, and developing support groups for HPN patients. 
 
HPN aims to transfer the techniques used in hospital to the home and create 
conditions that allow patients to lead as active and fulfilling a life as possible.   The 
Scottish Managed Clinical Network (MCN) for HPN set out criteria by which patients 
are selected for HPN therapy in Scotland. 
• Patients considered for entry into a HPN programme should have documented 
IF which if untreated would lead to deteriorating nutritional and/or fluid status. 
• Except in cases of short bowel syndrome with small bowel length of less than 
50cm patients should have undergone a trial of enteral nutrition 
• A clinician with an interest in and experience with IF, should assess patients 
with documented nutritional failure but no diagnosis.  
• Training for HPN for up to a month requires the patient to be physically able 
to cope 
• The ability of the patient to co-operate and preferences should be taken into 
account when assessing for HPN.   An assessment should be made of the 
appropriateness of the domestic circumstances (Scottish Home Parenteral Nutrition 
Managed Clinical Network 2009) 
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• When HPN is given to patients with gastrointestinal obstruction secondary to 
cancer, patients must be unable to tolerate oral or enteral nutrition, willing to comply 
with HPN, have an expected survival of more than 3 months, an awareness of their 
diagnosis and prognosis and appropriate home support (Bozzetti, Cozzaglio et al. 
2002). 
There are a number of relative contra-indications for parenteral nutrition at home.   
These include patients with uncontrolled diabetes – especially those patients on 
insulin therapy who continue to experience significant fluctuations in blood glucose 
despite optimisation of insulin dosing and regimen, and patients with electrolyte 
abnormalities (of potassium, phosphate  or magnesium for example) that are not easily 
corrected following replacement (Newton, DeLegge 2007).   These comprise relative 
contra-indications, and parenteral nutrition at home may still be considered for these 
patients with appropriate supervision. 
 
HPN is usually administered through a central vein catheter.   It is normally given 
overnight as an all-in-one feed of approximately 3 litres, and on average administered 
five nights per week, with a wide range of between 2 and 7 nights.   Some patients 
need saline and electrolytes bags instead of, or in addition to nutrition bags.   This will 
depend on the length and type of bowel remaining and the presence or absence of a 
stoma.   The catheter is situated so that its tip lies at the junction of the superior vena 
cava and right atrium.   The most commonly used type has a subcutaneous cuff to 
prevent external migration and is capped off externally when not in use.   A less 
frequently used catheter has an implantable port, which is cosmetically more 
desirable, but has a finite lifespan and cannot be repaired, necessitating surgical 
removal if problems occur. 
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A fridge is installed in the patient’s home solely for the purpose of storing the 
feedbags.   The nutrient content varies according to the pathology and length of time 
on parenteral nutrition.   Bags typically contain protein, glucose and lipid, electrolytes 
and vitamins. 
 
The training and preparation of a patient for HPN can last between 3 weeks and 3 
months and takes place concomitantly with treatment of the underlying disorder 
where possible.   The aim of the education is to allow the patient to move from a 
passive dependence on professionals to an active participation and independence.   
Adequate and successful training will achieve a situation whereby the patient 
understands their illness, has confidence in managing their own HPN and has 
developed a good relationship with the nutrition team (Nightingale 2001a).   In recent 
years, there has been a trend towards patients living in nursing homes, rather than in 
their own homes, with BANS data from 2000 documenting 5.8% of new registrations 
involving nursing home residents.   This change has important implications for the 
additional training of nursing home staff in HPN administration (Elia, Stratton et al. 
2002). 
 
1.10 Provision of HPN 
In the United Kingdom, patients suitable for HPN must be able to attend either a local 
nutrition team or a national IF centre.   If neither is available, access to HPN treatment 
is denied.   It is an important consideration whether the distances travelled by patients 
and their families for training, follow up and emergencies are manageable, especially 
with the increasing numbers of elderly patients commencing HPN therapy.   It has 
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been documented that patients with a longer journey time are less inclined to present 
with symptoms and have an inevitably prolonged time to diagnosis and assessment of 
serious complications (Jones 2003). 
 
In 1992 in the UK, the King’s fund recommended that all acute hospitals have a 
functioning nutrition support team (NST).  In 1999, only 41% hospitals had followed 
this recommendation (Jones 2001).   The most recent figures suggest that only 55% of 
adult centres contributing to the BANS report in 2003 had a NST (BANS ).   Despite 
this, it is a requirement that centres managing HPN patients have an NST, which 
comprises some or all of:  nutrition nurse, physician, surgeon, dietician and 
pharmacist.   In Europe, a different approach is followed.   In France, there are only 
fourteen HPN centres and much of the follow up work is carried out in primary care.   
In Denmark, all patients are managed from a single expert centre.   In England, the 
two IF units manage approximately 50% of the patients, whilst the other 50% are 
distributed amongst another 50 centres, many with only one or two patients 
intermittently (Jones 2001).   In Scotland, a Managed Clinical Network has been set 
up to provide a facility whereby patients can be managed locally under national 
guidelines. 
 
Outside of Europe, new Australasian guidelines have been published which by 
consensus opinion state similar criteria to other countries for commencing HPN, 
support the existence of a nutrition support team where possible for their patients and 
like Scotland, recognizes that some patients are living distant from centres with 
expertise in the care of patients on HPN and aim to provide support and 
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recommendations to clinicians caring for HPN patients in remote situation as well as 
in established centres of expertise (Gillanders, Angstmann et al. 2008). 
 
American HPN patients are managed quite differently, mainly by the pharmaceutical 
home infusion staff, with individual physicians overseeing HPN in single patients or 
sometimes small groups of patients, and less than 20% of patients being managed by 
large medical institutions caring for upwards of 25 patients.   This has been as a result 
of financial concerns regarding reimbursement to medical professionals for the time 
consuming nature of this work.   The American Society for Parenteral and Enteral 
Nutrition (ASPEN), has published guidelines on monitoring patients which concur 
with the Scottish guidelines advocating multi professional management of patients.   
They also strongly emphasise the importance of patient participation in recognizing 
problems and ensuring appropriate monitoring (Siepler 2007). 
 
The Scottish Home Parenteral Nutrition Managed Clinical Network (SHPNMCN) 
The concept of MCNs began with the publication of The Acute Services Review of 
the National Health Service in Scotland in 1998.   The aim of the network is to 
formalise previously informal arrangements to allow equity of access to optimal care 
via evidenced based procedures and a set of protocols.   HPN treatment in Scotland 
was considered to be suitable for the formation of an MCN, as it is a treatment 
whereby it is beneficial to be treated in an experienced centre yet issues of equity of 
access and care exist due to geographical remoteness.   The HPN MCN was 
established in 2000 and is funded by the National Services Division of the Common 
Services Agency on behalf of the Scottish Executive.   Members are multiprofessional 
in origin, spanning all the expertise necessary for the safe provision of HPN and in 
  
27 
27 
addition there is patient representation.   In contrast to the UK as a whole, the HPN 
MCN is confident of its numbers of HPN patients, as communication throughout the 
network is excellent and the coordinator is in close contact with all nutrition teams.   
When the MCN was formed, locally prepared protocols were reviewed and consensus 
opinion used to agree MCN national protocols that are followed locally by each 
hospital.   A quality assurance framework is in place to ensure standards and safety of 
HPN delivery.   The Clinical Standards Board for Scotland, now known as Quality 
Improvement Scotland, has provided approval.   A computer database collects data 
prospectively from all HPN sites in Scotland, allowing both national audits and the 
facility for research across a whole patient population.   The resource of an MCN can 
increase adherence to protocols, which has been shown to lessen complication rates 
(BAXTER, MCKEE 2003; Santarpia, Pasanisi et al. 2002).   Additionally it provides 
a large amount of experience, a support network and an ongoing education, which in 
previous studies both in the UK and abroad, have been linked to complication rate 
reduction and an improved outcome (BAXTER, MCKEE 2003; Smith, Curtas et al. 
2002b; Reimund, Arondel et al. 2002; Johnston, Richards et al. 1994).   The logistics 
of delivery and the provision of equipment has now become standardised across 
Scotland due to National Procurement securing a contract with a single 
pharmaceutical company to supply and deliver all necessary equipment and feed. 
 
1.11 Cost effectiveness of HPN 
HPN must compete for limited NHS resources.   When the expense of HPN is 
considered, it is surprising that, to date, more studies have not addressed the economic 
cost effectiveness of this treatment.   A cost-analysis by Richards et al 1997, stated 
that the first year cost of HPN per patient was £43 000.   The marginal cost per QALY 
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was £63 000.   The annual cost of hospital total parenteral nutrition (TPN) per patient 
was found to be £93 000, giving a 65% saving in financial terms alone by facilitating 
a HPN service and discharging patients from hospital.   An older study by Wateska et 
al supports this finding, noting a cost reduction of 73% for HPN.   Subsequent years 
of HPN treatment were found to cost £36 000 per annum (Richards, Deeks et al. 
1997).   Periodic review of patients was recommended by Baptista et al to ensure 
prescriptions, equipment and patient behaviours were regularly assessed to optimise 
costs.   More specifically, even less is known regarding cost effectiveness in 
subgroups of HPN patients such as those with malignant disease or AIDS.   If these 
patients were included the cost per QALY would increase dramatically.   Other 
questions raised by Richards et al were whether there was any financial benefit to 
different organisational models, for instance small or large HPN units.   This was 
addressed by Curtas et al who recognised the cost of a nutrition support team, the 
inference being that the greater the number of patients followed by a team, the lower 
the cost per patient (Curtas, Hariri et al. 1996). 
 
In Scotland, the issue of cost has been addressed recently by the MCN. A national 
contract has been awarded to provide HPN to all patients across the country.   Regular 
reports on key performance indicators are provided and since the contract was 
implemented in 2007 approximately £725 000 has been saved between new and 
existing HPN patients. 
 
1.12 Outcome of HPN therapy 
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It is established that HPN patients’ outcome is the product of factors such as 
underlying disease, general clinical condition, level of support by professionals and 
family, education and facilities (Bozzetti 2003). 
 
Data collected by the British Artificial Nutrition Survey demonstrate 92% overall one 
year survival of UK patients receiving HPN (Jones 2003).   In comparison, recent 
retrospective studies from North America and Europe report five-year survival of 
patients receiving HPN to be within the range of 60% to 78% (Messing, Crenn et al. 
1999; Vantini, Benini et al. 2004; Jeppesen, Staun et al. 1998; Scolapio, Fleming et al. 
1999; Lloyd, Vega et al. 2006).   The majority of these studies were carried out in 
centres of excellence.   Factors found to be associated with a poorer prognosis include 
small bowel length <50cm, age at initiation of HPN and the underlying diagnosis 
(Vantini, Benini et al. 2004; Scolapio, Fleming et al. 1999).   Patients less than 40 
years old and those with inflammatory bowel disease have been found to have the best 
prognosis (Pironi, Paganelli et al. 2003). 
 
Parenteral nutrition dependence is a second outcome examined in cases of short bowel 
syndrome.   The syndrome can be associated with either transient or permanent 
intestinal failure.   The probability of PN dependence is associated with length of 
small bowel remnant and type of anastomosis present.   Parenteral nutrition 
dependence was found to be 49% at two years and 45% at five years.   Intestinal 
transplantation is a viable alternative to HPN for patients with irreversible intestinal 
failure.   This is as a result of both improved patient and graft survival.   The 
importance of determining long term PN dependence and survival statistics in the 
SBS group of patients is to facilitate the decision of when and if to consider intestinal 
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transplantation.   It is useful and valuable therefore, to identify patients with 
particularly poor prognoses on HPN and whether this is as a result of their parenteral 
nutrition or their underlying disease process (Lloyd, Vega et al. 2006). 
 
Most HPN studies reporting outcome data have generally had either single centre 
experience or experience of tertiary referral centres where large numbers of highly 
selected intestinal failure patients are treated.   Patients in UK tertiary centres are 
broadly from two subpopulations, those who are well enough to travel the distances to 
the Intestinal Failure units and those who are highly complex and sent from around 
the UK to be managed in expert centres.   Of interest would be a study whereby all 
comers to the treatment are included and their data analysed.  In Scotland, the 
Managed Clinical Network provides HPN locally throughout Scotland and 
consequently a study of Scotland’s HPN patients provides the chance to review a 
complete population of patients.   As a result of the network and the consequent 
availability of HPN across this wide geographical area, we are provided with this 
diverse demographic to consider. 
 
1.13 Intestinal transplantation as an alternative 
Intestinal transplantation has shown huge advancement over the past decade, in both 
volume of operations performed and also in outcome.   The majority of operations are 
carried out in the United States where the number of patients listed has increased 
steadily from 87 in 1997 to 236 in 2006.   The median time to transplant is one of the 
longest of any solid organ, with a current average of 261 days and mortality remains 
high whilst on the waiting list, more than double all other solid organs (Freeman, 
Steffick et al. 2008).   Expected survival following intestinal transplantation remains 
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lower than expected survival on HPN, making HPN the treatment of choice for 
irreversible chronic intestinal failure, on both safety and efficacy grounds.   As such, 
the main indication for intestinal transplant is failure of HPN due to life threatening 
complications or lack of venous access; another is a locally invasive tumour of the 
abdomen.   Other than these, there are no absolute indications for considering 
intestinal transplant; however some patients are simply unwilling to contemplate life-
long intravenous nutrition (Pironi, Paganelli et al. 2003).   In 2005, a study in Europe 
was undertaken to examine the need for intestinal transplant, based on American 
criteria.   It found that the rate and indications for candidacy differed between adults 
and children, with paediatric rates twice as high as adult ones.   Adult indications were 
mainly related to failure of HPN whereas a high risk of death related to the underlying 
condition (pre-emptive intestinal transplantation) was most common in the paediatric 
population.   It also concluded that, in general, doctors had a reserved attitude towards 
intestinal transplantation and that this may be resulting in late referrals to the waiting 
list.   There was huge variation between countries in timing of referral, due mainly to 
the lack of guidelines (Pironi, Hebuterne et al. 2006).   In America, insurance agencies 
approve payment for intestinal transplant when life-threatening HPN complications 
occur.   The American Society of Transplantation considers paediatric indications to 
be similar but additionally include children with a high risk of death or very poor 
quality of life related to the underlying IF.   The outcome following intestinal 
transplantation is improving, and although still behind other solid organ transplants, 
the major development in immunosuppression in the nineties has seen the one-year 
survival improve to above 50% (Middleton, Jamieson 2005; Sudan 2007).   In the UK 
published literature, only 14 adult transplantations have been undertaken over the last 
15 years, despite the numbers of patients receiving HPN increasing steadily 
  
32 
32 
(Middleton, Jamieson 2005).   A poster at the British Association of Parenteral and 
Enteral Nutrition conference in October 2010 reported the results of a single UK 
centre over the last three years.   Thirteen transplants were performed over the last 
three years with an overall 92% survival, including one death due to occult 
malignancy (Wiles, Butler et al. 2010). 
 
1.14 Complications of HPN 
HPN shares all the complications of parenteral nutrition, yet additionally, it has its 
own specific problems related to the long term nature and complexities of the 
treatment.   These problems can lessen the success of HPN and can also adversely 
affect quality of life and influence prognosis.  At their most serious, HPN related 
complications can be fatal (Pennington 1991).   The patient also has the underlying 
disease to contend with, and the natural progression of this can further complicate the 
satisfactory delivery of HPN (Jones 2001).   HPN related complications fall into 
categories including catheter related sepsis, venous thrombosis, mechanical and 
metabolic problems. 
 
1.15 Macronutrients 
The macronutrients protein, carbohydrate and lipid are substrates for anabolism and 
energy production.   Their effects are dependent on both their relative concentrations 
and the recipient individual.  If the amounts provided are below that of the 
Recommended Daily Allowances (RDA), tissues are broken down to provide the 
missing energy.   If excess macronutrients are supplied, they are stored as glycogen or 
fat.   In the healthy subject, the provision of macronutrients ensures the maintenance 
of lean body mass.   In contrast, sick patients are in a catabolic state and nutrients 
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prevent loss of further lean body mass in addition to repairing wounds and aiding 
healing.   Nutritional requirements themselves do not differ in these groups of patients 
but quantities and proportions of amino acids, carbohydrates and lipids may vary.   
Requirements are determined by nutritional status assessment and taking into account 
the specific diagnosis of the patient, which can imply specific deficiencies. 
 
1.16 Micronutrients 
Micronutrients can be difficult to measure, and as such knowledge of requirements is 
minimal, especially in disease states, but they are known to have two main functions.   
Firstly, micronutrients have a key role in intermediary metabolism as cofactors or 
coenzymes in enzyme-catalysed reactions.   Secondly, they are part of the free radical 
scavenging system, whereby they protect tissues from the reactive oxygen species 
generated by the metabolic response to disease.   Increasing degrees of micronutrient 
deficiency have a progressive effect on patients before a clinical deficiency syndrome 
is reached and diagnosed.   Depletion initially leads to reduced body content, followed 
by a reduction in both metabolite synthesis and cellular metabolism through the lack 
of vitamin-dependent enzymes and hormones (Shenkin 2001). 
 
Most patients who require HPN will have been in hospital for a substantial period and 
will have been stabilized on an appropriate micronutrient regimen for their 
requirements.  Some patients may still have issues with tissue mass to regain and 
stoma losses to compensate for.   The micronutrients in HPN preparations are based 
on the nutritional requirements of patients who are catabolic or already malnourished 
and therefore are designed to provide more than the Reference Nutrient Intake, 
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delivered intravenously they should more than meet requirements for most 
individuals.    
 
It is still possible for patients receiving HPN to develop micronutrient deficiencies for 
several reasons.   Sometimes micronutrients are actively withheld from patients.   This 
is seen in cholestasis, when manganese and copper, which both undergo biliary 
excretion, are withheld to prevent a toxic accumulation of either nutrient.   Patients 
who consume some oral diet are assumed to gain a proportion of their micronutrients 
this way; this is entirely dependent on the diet consumed and its nutritional value.   
Additionally, there is a potential risk of nutrient degradation within the HPN mixture 
or chemical changes for nutrients such as ascorbic acid, thiamine, riboflavin, zinc and 
copper (Bozzetti, Staun et al. 2006). 
 
Approximately thirty percent of HPN patients may have a micronutrient deficiency 
but this rarely causes clinical consequence.   The most common deficiency is of iron, 
which resolves with supplementation (Forbes, Forbes 1997).   A study by Forbes and 
Forbes (1997) found concomitant folate deficiency in two iron-deficient patients and 
illustrates the importance of considering the presence of other deficiencies when 
anaemia is diagnosed.   The same study investigated the incidence and nature of 
clinical micronutrient abnormalities within their HPN population.   Micronutrient 
assays were performed and all patients studied had at least one micronutrient level 
outside the reference range.   All but one of the 32 patients had an abnormally raised 
manganese level.   On clinical review, it was not possible to determine the individuals 
with these abnormalities.   The study concluded that abnormalities of micronutrient 
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levels are common in HPN patients but serious sequelae are unusual (Forbes, Forbes 
1997). 
 
Micronutrient deficiencies with known consequences include cardiomyopathy from 
severe selenium deficiency and neuropathy with too little vitamin E.   Selenium doses 
in HPN are believed to be sufficient for maintaining selenium status but are 
inadequate for replacing depleted stores or for patients with an increased demand 
(Malone, Shenkin et al. 1989).   A case study of zinc deficiency highlights the need 
for addition of this essential component to HPN.   A vesicular pustular rash was noted 
and early ulcerations were present on the fingers of a patient receiving long term 
parenteral nutrition without zinc addition.   Serum trace elements confirmed zinc 
deficiency and the dermatological condition resolved with intensive zinc 
supplementation (Jones, Lamb et al. 2007). Copper deficiency in patients on TPN 
usually manifests clinically after several months as haematological abnormalities e.g. 
leukopaenia, neutropenia and anaemia (Fleming 1989). 
 
For most micronutrients, the safety margin between adequate provision and toxic dose 
is large and there is minimal risk of excessive provision.   However, HPN can 
occasionally result in an excess of micronutrients due to the non-physiological 
delivery of the nutrition, which bypasses the regulatory role of the liver and makes 
them 100% bioavailable.   Metals can accumulate in the tissues in this way.   Over 
50% of HPN patients may have elevated blood levels of manganese and over the 
years there have been multiple reports of excess manganese accumulating in the brain 
of HPN patients, presenting with Parkinsonian symptoms.   This is thought to be 
either secondary to excess provision or inadequate biliary excretion.   Cholestasis is 
  
36 
36 
likely to be less important than excess provision (Wardle, Forbes et al. 1999), 
although patients with chronic inflammation are more likely to develop 
hypermanganesaemia, with abnormal biochemical LFTs (Reimund, Dietemann et al. 
2000).   Manganese deficiency in humans is rare and growing evidence of the 
frequency of manganese toxicity suggests that parenteral supplementation may be too 
high.   A combination of PN contamination with manganese and dietary sources in 
those patients managing some oral diet may be contributory, and even be sufficient to 
withdraw manganese from trace element mixtures (Hardy, Gillanders et al. 2008).   
Chromium has also been reported in high levels, and this seems to be through a 
mixture of intentional provision to avoid a deficiency state, and the contamination of 
parenteral nutrition solutions with chromium.   The consequences of chromium excess 
are not clear (Bozzetti, Staun et al. 2006).   A third trace element to accumulate is 
copper.   This is believed to be due to the disruption of the enterohepatic circulation 
and cholestastic liver disease and is independent of duration of HPN therapy (Blaszyk, 
Wild et al. 2005). 
 
Metabolic bone disease (MBD) is a complex and common problem in patients 
receiving HPN.   It can be a major cause of morbidity and because of this patients 
should be monitored regularly for both osteomalacia and osteoporosis.   Equally it can 
be asymptomatic and the diagnosis is at times incidental.   Risk factors for MBD 
include the underlying disease and its consequent treatments, such as radical surgery 
and long-term corticosteroids through renal calcium excretion, prolonged inactivity, 
and smoking.   Patients can begin their HPN with pre-existing calcium and 
magnesium deficiencies and vitamin D-deficient osteomalacia.   Symptoms of this, 
including periarticular bone pain and tenderness, often worsen as HPN therapy is 
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established, due to weight gain and growth; this is known as the ‘paradox of rickets’ 
(Jones 2001).  In 2000, an Italian study compared HPN patients of less than four 
months with patients of greater than twelve months duration and showed that initially 
bone turnover increased.   After six months this turnover returned to normal but bone 
formation was increased, this also settled to low or normal rates after one year of 
treatment (Pironi, Labate et al. 2002).   However, in contrast, a Canadian group led by 
Jeejeebhoy concluded that the bony pains are due to vitamin D-induced osteomalacia 
which can recover when vitamin D is withheld from HPN bags (Jeejeebhoy 1998).   
Osteoporosis is a debilitating problem found with long term HPN.   These patients 
have an excessive urinary excretion of calcium and phosphorus, but normal serum 
biochemistry including vitamin D (Pennington 1991).   Magnesium deficiency 
inhibits parathyroid hormone secretion, the consequence of which is decreased 
calcium absorption from the gut.   Correction of magnesium, calcium and phosphorus 
levels help to minimise osteoporotic changes, light weight-bearing exercise is 
encouraged and either regular oral, or annual intravenous, bisphosphonates (which 
circumvent the variable bioavailability due to short gut syndrome in HPN patients) are 
frequently used (Staun, Pironi et al 2009).   In addition, recombinant parathyroid 
hormone may be used in the treatment of MBD in HPN patients.   The role of vitamin 
D in bone disease remains inconclusive (Btaiche, Khalidi 2004).   All patients should 
have bone densitometry performed (DEXA scanning) when entering an HPN 
programme and thereafter yearly or when metabolic bone disease is suspected 
(Buchman, Moukarzel 2000). 
 
1.17 Metabolic complications of HPN 
  
38 
38 
Many diseases have both qualitatively and quantitatively abnormal requirements and 
in some patients, disease states can render non-essential nutrients essential due to a 
compromised biosynthetic capacity.   Additionally, parenteral nutrition solutions are 
anabolic in nature, and in the acute setting, refeeding a malnourished patient can 
precipitate a deficiency state (Thorell, Nordenstrom 2001).   The most important 
nutrient deficiencies are hypoglycaemia and hypophosphataemia.   Rebound 
hypoglycaemia can occur due to high insulin levels if feed is stopped abruptly.   
Patients may be taught to reduce the rate of infusion gradually to prevent this 
problem.   An extracellular hypophosphataemia is caused by the intracellular influx of 
phosphate in response to carbohydrate load and insulin release (Thorell, Nordenstrom 
2001).   Severe hypophosphataemia results in a decrease in function of multiple 
systems including respiratory, cardiac and neurological.   The addition of phosphate to 
the feed prevents this rare but serious complication of short term parenteral nutrition. 
 
1.18 Hepatobiliary complications 
Patients receiving home parenteral nutrition are at risk of developing hepatobiliary 
complications ranging from mildly deranged liver function tests (LFTs) to life 
threatening end stage liver disease.   This can present late and in this situation is often 
irreversible, the only possibility of recovery through combined liver and small bowel 
transplantation.   Data from the International Transplant Registry (2001) suggests that 
55% of patients with HPN-related liver disease require a combined liver/intestinal 
transplant at the time of referral.   The incidence of liver complications increases with 
duration of parenteral nutrition (Henkel, Buchman 2006).   Cavicchi et al showed this 
by demonstrating that the prevalence of chronic cholestasis (two of alanine 
aminotransferase, aspartate aminotransferase, alkaline phosphatase raised to 1.5 times 
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their normal level for greater than six months) increases with duration of HPN, 55% at 
2 years, 64% at 4 years and 72% at 6 years (Cavicchi, Beau et al. 2000).   Many 
studies have examined the aetiology of HPN-associated liver dysfunction and no 
single factor has been identified.   Liver disease is more common in children and in 
short bowel patients, remnant small bowel<50cms, although this is thought possibly 
to be directly related to the consequent provision of HPN for long durations (Lloyd, 
Zabron et al. 2008), small bowel bacterial overgrowth, bowel rest and disruption of 
bile acid (Chan, McCowen et al. 1999; Btaiche, Khalidi 2004).   Excessive dextrose or 
total calories, proportionally excessive calories derived from lipids, choline 
deficiency, essential fatty acid deficiency and hepatotoxins have all been implicated 
(Chan, McCowen et al. 1999).   Current research is focussed on hepatic 
transulphuration pathways as a contributor to HPN-related liver disease.   Methionine 
is the only sulphur-containing amino acid in HPN due to its solubility.   Intravenous 
delivery avoids the physiological portal system and methionine is transaminated to 
mecaptans rather than normal downstream products important in mobilising fat and 
synthesising lipid membranes for bile secretion (Howard, Ashley 2003).   Other 
reasons for deranged liver function include pre-existing illness such as Crohn’s 
disease and multiple episodes of sepsis.   Crohn’s may lead to abnormal liver function 
via a number of routes.   Primary sclerosing cholangitis – presenting typically with an 
elevation in alkaline phosphatase or gamme GT – may affect 5% of patients with 
Crohn’s disease.   Cyclical infusion of HPN has been found to reduce the incidence of 
liver-related complications when compared with continuous infusions.   Medical 
treatment options for HPN-related liver disease include encouraging oral intake, 
limiting parenteral lipid calories, treatment of bacterial overgrowth with prokinetic 
agents and antibiotics, oral or parenteral provision of carnitine and choline and the 
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prescription of ursodeoxycholic acid, which is thought to work by correcting the bile 
salts.   In the absence of oral or enteral nutrition, about 25% of HPN patients develop 
cholelithiasis secondary to the lack of cholecystokinin release and consequent 
decreased gallbladder contractility.   The bile accumulation leads to the formation of 
cholesterol stones in the gallbladder and the development of a biliary sludge.  Most 
surgeons do not remove the gallbladder prophylactically at the time of the initial 
surgery and patients undergo cholecystectomy only if they develop problematic 
gallstones (Howard, Ashley 2003). 
 
1.19 Catheter related complications of HPN 
In a systematic review of HPN in 1997, Richards et al reported that catheter sepsis 
occurred at a rate of 0.34 episodes per catheter year, which equates to one episode 
every 2-3 years.   Similarly, catheter occlusion and central venous thrombosis were 
reported to have incidences of 0.071 and 0.027 episodes per year respectively.   More 
common were problems with fluid and electrolyte imbalance at between 0.12 and 0.61 
episodes per year (Richards, Deeks et al. 1997).   A study at the Mayo Clinic reported 
that of their 225 HPN patients over the past 20 years, 45% had needed no further 
hospitalisation following their commencement on therapy, a further 48% required 
between 1 and 6 readmissions.   The most common reason for admission was catheter 
related infection, followed by electrolyte disturbance, liver disease and metabolic 
bone disease (Scolapio, Fleming et al. 1999). 
 
Fever can have many causes in a patient receiving HPN.   One important differential 
to be considered and excluded is that of catheter related sepsis.   Symptoms and signs 
are often sub clinical and subtle and so a high degree of suspicion is necessary.   On 
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average, this occurs every 2-3 years in adults and with twice this frequency in 
children.   Patients receiving HPN for prolonged periods benefit from a decreased rate 
of catheter infection (Buchman, Moukarzel et al. 1994).   Catheter related infection is 
the most common reason for readmission to hospital so prevention is very important 
both for the patient and for the cost effectiveness of the treatment.   The most valuable 
tool for this is patient education and training by an experienced HPN nurse, and this 
appears to be most beneficial if tailored to the individual patient, taking into account 
intellectual and manual skill level (Reimund, Arondel et al. 2002).   The preventative 
role of careful training is further supported by a French study which found that 
patients given detailed written information together with several theory and practical 
sessions and often a monthly follow up did significantly better with regard to catheter 
infection (8%) than patients given more brief instruction and no follow up (21%) 
(Santarpia, Pasanisi et al. 2002).   Also significant is the experience of the hospital 
managing the HPN.   There is a documented inverse correlation between the incidence 
of catheter related infection and a teams’ experience level with HPN (Johnston, 
Richards et al. 1994, Mughal, Irving 1986) and even within a team, the number and 
frequency of catheter infection can be shown to decrease as the team gains experience 
(Reimund, Arondel et al. 2002). 
 
Patients with motor disorders have increased catheter infection rates, presumably 
through a high rate of bacterial translocation (Reimund, Arondel et al. 2002).   It is 
possible that this is also the case in short bowel syndrome where mucosal integrity is 
altered by the physiological adaptation (de Burgoa, Seidner et al. 2006).   There is a 
trend towards higher rates of catheter related infection in patients with stomas or 
fistulae.   A study by O’Keefe et al of his HPN patients concluded that a jejunostomy 
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was a risk factor for catheter related infection, speculating that the mechanism of this 
is most likely to be touch contamination (O'Keefe, Burnes et al. 1994). 
 
Conditions surrounding the placement of the intravenous catheters can also have a 
significant effect on whether subsequent infections develop.   Biofilms form as a 
matter of course on both the external and internal catheter surfaces and it is the 
dispersal and dissemination of the biofilm bacteria into the bloodstream which causes 
catheter-related blood stream infections (CRBSI).   Bacteria are impacted on the tip of 
the needle as it traverses the epidermis during insertion.   Effective skin cleansing 
prior to insertion of the catheter can fundamentally and significantly affect rates of 
extraluminal CRBSI.   In addition, chlorhexidine gluconate impregnated dressings can 
significantly reduce CRBSI rate when compared to transparent polyurethane film 
dressings.   Intraluminal infections are a major source of CRBSI in long term catheters 
and  can be minimised by a combination of hand hygiene, access site disinfection and 
antimicrobial flush solutions after use (Ryder 2006).   Diagnosis of CRBSI is usually 
by positive blood cultures obtained through the catheter as well as peripherally.   A 
more precise and advanced diagnostic technique is that of obtaining a quantitative 
catheter blood culture value whereby the central culture is five-fold greater than the 
value obtained peripherally.   The original management of CRBSI was to remove the 
infected line and treat systemically with antibiotics.   As central venous access is a 
precious commodity in HPN patients, treatment has progressed to use an antibiotic 
lock within the catheter wherever possible to prevent loss of the catheter.   There are 
occasion when infections with specific bacteria render line preservation potentially 
harmful, with the possibility of metastatic infection (particularly in the case of 
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Staphylococcal infection).   In these circumstances, line removal is the preferable 
course of action. 
 
Catheter occlusion can occur as a result of fibrin, lipid or amorphous debris build up 
on the intraluminal surface of the catheter.   When blood is left within the lumen of 
the catheter, a thrombotic occlusion may also develop.   These complications are 
minimised by two interventions, catheter flushing and the use of antireflux needleless 
connectors and valves (Ryder 2006).   A positive correlation between thrombotic 
occlusion and catheter infection has been described (de Burgoa, Seidner et al. 2006). 
 
Catheter fracture is a further serious complication which all HPN patients are warned 
of prior to discharge from hospital.   There is a risk of air embolism, haemorrhage or 
infection when the integrity of the catheter is lost (Pennington 1991).   Patients are 
taught to clamp the line before seeking help from health care professionals.   The 
problem usually occurs close to the hub of the catheter where it is clamped and as 
such, most patients now use an extension tube which can be changed regularly to 
avoid wearing.   Increased incidence of fracture is suggested with the practice of 
intraluminal brushing used to unblock catheters and aid precise diagnosis of catheter 
related infection (Jones 2001). 
 
HPN patients are at risk of central venous thrombosis (CVT) for several reasons 
including suboptimal catheter positioning, underlying condition and prothrombotic 
HPN components.   It is well established that catheters placed in the superior vena 
cava (SVC) instead of the right atrium are at an increased risk of thrombosis 
(Pennington 1991).   Underlying conditions predisposing to CVT include Crohn’s 
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disease, due to the platelet abnormalities present, the prothrombotic tendencies of 
neoplastic diseases (Pennington 1991) and the primary coagulation disorder in 
mesenteric infarction. (Messing, Hebuterne et al. 2001).   With respect to Crohn’s 
disease, platelet abnormalities include thrombocythaemia and hypersensitivity to 
agonists including epinephrine, collagen and adenosine diphosphate (Matsumoto 
2006).   Further to this, malnutrition presents additional risks of essential fatty acid 
deficiency and hyperhomocysteinaemia for all HPN patients (Compher, Kinosian et 
al. 2001).   Following the establishment of a relationship between glucose 
concentration and CVT, a study by Pennington et al found that modifying the glucose 
concentration in HPN bags led to a significant fall in CVT rates over subsequent years 
(Johnston, Richards et al. 1994). 
 
1.20 Paediatric HPN 
The natural history of intestinal failure in children is variable.   Most children with 
acute IF, usually secondary to gastrointestinal infection, recover with appropriate 
treatment.   Paediatric cases of short bowel syndrome leading to chronic intestinal 
failure are often secondary to surgery for congenital anomalies or necrotizing 
enterocolitis.   They generally retain their colon and adapt gradually over several 
years, enabling them eventually to cease HPN.   In addition, there are children with 
severe chronic intestinal failure, who without long term parenteral nutrition or, when 
possible, small bowel transplantation would not survive.   Paediatric diagnoses 
leading to lifelong HPN dependence include mucosal diseases such as congenital 
microvillus atrophy and neuromuscular disorders for example chronic intestinal 
pseudo obstruction (Milla 2001).   Ethical dilemmas are addressed and decisions made 
after careful discussion with parents and professionals.   
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To formulate paediatric feeds, a regimen is calculated per kilogram body weight per 
day.   In cases of long term growth failure, caloric intake is related to expected rather 
than actual weight.   Complications with paediatric parenteral nutrition are dominated 
by catheter problems, as in the adult patient.  Catheter sepsis should be suspected 
when infection is queried but no source is known.   It is more common in children 
than in adult patients and may be associated with non-specific symptoms and signs 
including fever, unstable blood sugar, diarrhoea and vomiting.   Causative agents may 
differ, with Gram negative isolates as common as Gram positive ones.   
Psychologically, failure to provide parenterally fed infants with oral nutrition or 
stimulation can lead to feeding difficulties or food rejection at a later stage.   This is 
minimised by involving speech and language therapists early and offering food or 
‘dummies’ where appropriate.   Other aspects to consider and limit are long periods of 
isolation during feeding and immobility due to pumps and other equipment (Puntis 
2001). 
 
1.21 Quality of life after starting HPN 
Quality of life (QoL) in HPN patients depends upon good technical skills, leading to 
fewer line infections and subsequent hospital admissions.   In 2005, Persoon et al, 
using questionnaires and interviews, found that most patients were attributing 
psychological symptoms to underlying disease processes rather than HPN treatment 
(Persoon, Huisman-de Waal et al. 2005).   Baxter et al also reviewed QoL findings of 
previous studies and concluded that separation of disease process and HPN 
technology issues would be required to better evaluate QoL and a disease specific 
HPN QOL would be ideal.   A later paper by Huisman-de Waal et al reviewed 
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multiple QoL studies in HPN patients and concluded that overall, HPN patients 
experience a moderate to good QoL, but that many suffer fatigue and depression, 
somatising psychological symptoms (Huisman-de Waal, Schoonhoven et al. 2007).   
Smith et al found that the patients supported by an organisation had a mean score 
indicating no (or mild) depression, while the mean scores for the patients who were 
not supported indicated moderate depression (Smith, Curtas et al. 2002a).   Anxiety 
was also a feature in many studies, common fears mentioned included the fear of 
death and of liver failure.   Worthy of note, levels of anxiety were found to be higher 
in HPN patients than in patients having undergone small bowel transplantation 
(DiMartini, Rovera et al. 1998).   An important indicator in the assessment of 
outcome.   Social aspects of life were also found to be compromised by HPN.   
Activities such as child care, shopping and sports were areas where patients had to 
make adaptations.   Going on holiday was problematic, and the logistical 
arrangements demanding.   However, the longer the patients were on HPN, the less 
the effect on travel (Huisman-de Waal, Schoonhoven et al. 2007; Chambers, Powell-
Tuck 2007). 
 
1.22 The Patient Perspective 
Since 1993, surveys have questioned and utilised patient opinion on all aspects of 
HPN.   This has helped appreciate and understand issues important to patients 
concerning this highly specialised treatment. 
 
The journey starts with a patient being told by medical staff that they would benefit 
from commencing parenteral nutrition.   After concerns regarding previous treatment 
failures and future challenges are discussed, the patient begins the process of 
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accepting the feeding tube and learning to use the equipment.   This takes a variable 
amount of time and a huge amount of support from specialist nursing staff and 
dieticians.   Once home, the patient and family must adjust and settle into a routine 
that suits.   There is telephone support available and follow up with nutrition support 
teams regularly.   Deliveries of feed and equipment are made regularly and feed must 
be refrigerated at a constant temperature until used.   Some patients manage to return 
to work and by arrangement travel on holiday to destinations where bags of feed can 
be delivered.   Parenteral nutrition bags have been delivered all over the world.   
Support groups such as PINNT (Patients on Intravenous and Nasogastric Nutrition 
Therapy) are established and provide a network of support and understanding from 
patients undergoing similar challenges. 
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Chapter 2 
Home Parenteral Nutrition in Scotland: Frequency of Monitoring, 
Adequacy of Review and Consequence for Complication Rates 
2.1 Introduction 
Parenteral nutrition can improve the recovery and survival of patients who would 
otherwise suffer from malnutrition.   However, it can itself be associated with adverse 
effects of mechanical, septic or metabolic origin (Nordenstrom 2001).   For HPN to be 
effective it is essential to ensure that the nutrients provided are adequate and are being 
utilized effectively.   Regular monitoring of HPN patients serves several purposes, 
including the assessment of general wellbeing, identifying and helping with possible 
problems in feeding technique and potential complications - as well as the assessment 
of nutritional intake and monitoring weight, laboratory data and other outcome 
factors.   By the time a patient is discharged from hospital he or she is likely to be 
more metabolically stable and monitoring does not need to be carried out as 
frequently as whilst an in-patient.   Few studies have been conducted to investigate the 
diagnostic efficacy or cost-effectiveness of monitoring patients receiving any form of 
nutritional support, and even less information is specific to HPN patients.   The NICE 
guideline recommends review by home care specialists and by experienced hospital 
teams, initially at least weekly.   Long term, it is recommended that review be 
undertaken three to six monthly at a specialist hospital clinic (National Collaborating 
Centre for Acute Care. Commissioned by the National Institute for Clinical 
Excellence 2006). 
 
Newly published ESPEN (European Society of Parenteral and Enteral Nutrition) 
guidelines on Parenteral Nutrition (Staun, Pironi et al. 2009) advise the monitoring of 
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biochemistry and anthropometry at all visits; vitamins and trace elements at six 
monthly intervals and investigations for metabolic bone disease annually.   ASPEN 
(American Society for Parenteral and Enteral Nutrition) (Siepler 2007) 
recommendations have some similarities to ESPEN such as annual bone densitometry.   
However, they also recommend slightly different intervals for monitoring other 
elements, with monthly to quarterly biochemistry and liver function tests, quarterly 
iron and folate, quarterly to annual trace elements and annual vitamins.   ASPEN also 
documents a requirement for annual quality of life assessments, the need for which is 
discussed in the European guidelines, without formally suggesting an interval for 
regular Quality of Life (QOL) measurement in their Summary of Statements. 
 
In Scotland, a patient receiving home parenteral nutrition benefits from the HPN 
Managed Clinical Network (MCN), which sets standards, approves protocols, 
conducts audit, measures outcomes and encourages multi professional care.   Due to 
the lack of published studies, the Scottish HPN MCN guidance, like that of NICE, is 
based on expert opinion rather than higher levels of evidence, and recommends that 
initially the patient should be observed closely and the first clinic visit should be 
within 1-2 weeks of discharge from hospital.   Thereafter, it is recommended that they 
are seen every three months as an out-patient (Baxter, McKee et al. 2007).   The HPN 
MCN guidelines state that the patients’ weight, haemoglobin, indices of inflammation 
such as white cell count and C-reactive protein (CRP), renal function, liver function, 
calcium and magnesium, micronutrients, vitamins and anthropometry should ideally 
be measured at each HPN review.   Anthropometry should include triceps skin fold 
thickness (TSF), mid upper arm circumference (MUC) and mid arm circumference 
(MAC). 
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Scottish, ESPEN and ASPEN guidelines are very similar with respect to most aspects 
of HPN monitoring, with the exception of anthropometry which is not mentioned in 
the American guidelines and their obligatory annual QOL surveys for which they use 
a generic quality of life assessment tool.   QOL measurement is not yet formalised in 
European guidelines, but a specific tool for measurement in HPN patients is being 
developed.   All three guidelines are based on experience as evidence based guidelines 
are not yet available. 
 
The aim of this study was to assess the degree to which this guidance on HPN 
monitoring by the Scottish HPN MCN is adhered to, and to determine whether any 
relationship exists between frequency of review and complication rate in HPN 
patients.  
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2.2 Materials and Methods 
All patients receiving HPN funded by the NHS (National Health Service) in Scotland 
are known to the MCN through both direct contact with the Network Manager and the 
National Contract for Parenteral Nutrition Provision in Scotland.   Patients were 
included in this study if they were on HPN for at least three consecutive months 
during 2006.   A figure of one hundred days was taken as the recommended frequency 
against which all patient reviews were compared.   Data was collected primarily from 
the purpose-built Microsoft Access database, which is completed by nutrition teams at 
all HPN MCN centres for each patient and each visit.   All patients receiving HPN in 
Scotland are entered prospectively on to the database, which holds patient data since 
the creation of the MCN in 2000.   Recorded information includes patient 
demographics, catheter and feed details, blood results, clinic review findings, 
complications and termination of treatment information.   Missing or queried data was 
resolved through personal visits to the hospitals concerned and review of patient notes 
or by contacting the local nutrition teams.   Patients were placed into three groups, 
dictated by how often their inter-review interval met the one hundred day guideline.   
Within the three groups, median time on HPN treatment was calculated to assess any 
correlation between regularity of review and duration of home parenteral nutrition.  
Complications were divided into HPN and disease related categories.   HPN 
complications included central venous line problems and metabolic concerns related 
to intravenous feeding.   Disease related complications covered issues secondary to 
the disease process as well as pre and post surgical problems.   The incidence of 
complications in each group was compared using a chi-squared test. 
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2.3 Ethics 
This study was discussed with the Glasgow Royal Infirmary Ethics Committee who 
deemed that the data was already being collected and stored with patient consent, 
prior to this study.   In view of this, no ethics committee approval was necessary.   All 
patients involved in this study are made aware of the ongoing collection of data and 
audit at the start of their treatment. 
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2.4 Results 
In 2006 a total of 53 patients received HPN in Scotland for three or more consecutive 
months.   The patients attended 141 HPN clinic appointments, an average of 2.6 
clinics per patient within the selected time frame.   There was a wide variation in the 
number of patients at different centres - between 1 and 20 for the studied year.   
Numbers of clinic appointments per hospital therefore also varied greatly between 2 
and 49 within 2006.   Patient demographics, range of diseases and HPN indications 
are found in Table 2.1.   Data was collected from seven of the nine nutrition hospitals 
responsible for overseeing HPN treatment.   Two Scottish hospitals had no patients 
meeting the inclusion criteria during the period examined and are therefore not 
represented in this study. 
 
The frequency of monitoring was considered in two ways.   Firstly, did patients’ 
review intervals meet the set standard?   When the database was examined, three 
broad groups of patients resulted.   Approximately one third fell into each group, with 
30% meeting the standard on all occasions, Group A, 36% meeting the standard on 
some of their visits during the studied year, Group B, and 34% never being reviewed 
within the set standard throughout 2006, Group C.   The range of interval length 
between reviews was considerable, with twenty-seven of the appointments (19%) 
more than two hundred days following the previous review.   However, there were 
twenty-five patients (45%) who breached the standard on just one occasion 
throughout the study period, with all other appointments meeting the target. 
 
Secondly, individual clinic reviews rather than patients were considered as to their 
frequency of monitoring.   Eighty-five clinic reviews (60%) met the standard of 
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review frequency.   Fifty six clinic outpatient clinic reviews (40%) were outwith the 
set standard.   The patients who were not seen within 100 days on every occasion 
were distributed between all seven hospitals.   Examining these clinic reviews by 
centre, the range of outpatient appointments meeting the target at individual centres 
varies between 0% and 77% however these results correspond to small hospitals with 
only one or two patients and two or three clinic appointments each.   One hospital 
never met the standard but this reflected the clinic reviews of just one patient.   The 
majority of hospitals had more patients and conducted between 40% and 67% of 
scheduled reviews within the guideline of 100 days.   Three patients were unable to 
attend scheduled clinic appointments and consequently were reviewed later than 
planned, despite the efforts of the local nutritional teams to provide alternative dates 
to accommodate them.   A further eight patients had blood taken and tested but no 
evidence of formal review. 
 
The adequacy of monitoring was also examined (Figure 2.1) Blood was taken at 131 
of the 141 appointments (93%).   Figure 2.2 shows the distribution of tests requested 
from the 131 samples taken.   Vitamins and micronutrients must be ordered separately 
from biochemistry and haematology requests and as such were analysed 
independently, being sent in 88 (62%) of reviews.   Figure 2.3 details the range of 
vitamins and micronutrients ordered.   
 
As a subset of this studied group, patients who were newly started on HPN were 
analysed separately.   Ten patients were commenced and remained on HPN in 
Scotland for at least three consecutive months during 2006.   These patients came 
from four of the seven centres studied.   A comparison of HPN indications for these 
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patients is detailed in Table 2.1.   All ten patients met the one hundred day standard on 
all of their twenty-four clinic appointments during 2006 and each attended an average 
of 2.4 clinics.  Weight was measured at 18 (75%) and anthropometry at 5 of the 24 
(21%) assessments.   Blood was taken at all 24 (100%) appointments and details of 
the tests ordered are seen in Figure 2.2 and Figure 2.3.   Various combinations of 
vitamins and micronutrients were measured at thirteen of the twenty-four clinics 
(54%); only two (8.3%) clinic reviews ordered a complete set of the recommended 
tests. 
 
Period of HPN treatment was calculated and median averages compared for the three 
groups, A, B and C (Table 2.1). 
 
We next considered the complications experienced by HPN patients together with the 
frequency of monitoring in order to establish whether any relationship links increased 
review interval with increased HPN-related complication rates.   For the majority of 
patients, complications are investigated on an inpatient basis and have no effect on 
outpatient review appointments.   These situations allowed us to look closely at 
complication rates and scheduled review appointments as independent factors and 
determine whether closer supervision has any consequence for HPN-related 
complications and admissions. 
 
Using the same three frequency of review groups, A, B and C, patients were identified 
who had had complications in 2006 and the three groups compared.   Demographics 
and underlying disease processes were similar in all three groups. (Table 2.1). The 
complications were divided into HPN-related and disease-related.   There were a total 
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of 34 complications recorded on the Microsoft Access database, which were classified 
as either HPN-related or disease-related. 
 
Of the fifty-three patients receiving HPN in Scotland in 2006, 16 patients (30%) had 
at least one complication reported to an HPN team.   Examining the total number of 
complications, Group A had more than double the number of complications of either 
Group B or Group C.   However, when the actual number of patients affected by the 
complications was investigated, the result was much closer for the three groups, with 
five patients in Group A, six in Group B and five in Group C.   It seems therefore that 
it is a minority of patients in each group who are each having multiple complications 
rather than all patients in any one group experiencing problems.   The vast majority of 
complications reported have been classified as HPN-related on the MCN database.   
Only two patients had both disease- and HPN-related complications over the time 
period studied, one patient each from Groups B and C.  
 
Statistical analysis was performed using a chi-squared test.   Ideally, the authors 
would have compared HPN complications with both non-HPN complications and no 
complications in a 3x3 table but with the small numbers involved two cells would 
have contained either zero or one.   In view of this, complications data was grouped 
into complication v no complication,  = 0.76 p = 0.963 and HPN complication v no 
HPN complication  = 0.229 p = 0.892. 
 
Only 3 patients were reported to have had a total of nine disease-related complications 
between them.   These included multiple episodes of small bowel obstruction or 
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abdominal distension, bleeding from a stoma, a medication related complication, a 
pulmonary embolus and an episode of intra abdominal sepsis. 
 
Eleven patients experienced 25 episodes of HPN-related complications during 2006, 
some patients experiencing multiple events during the year. (Table 2.1).   Of the HPN-
related complications reported, the vast majority were intravenous catheter-related 
(mostly line infections) but with two episodes of venous thrombosis and three of 
mechanical failure with broken or split lines.   Additionally, there were seven reported 
cases of metabolic complications, usually dehydration due to inadequate parenteral 
fluid volume.   Three of ten patients reporting line infections were in Group A, three 
were in Group B and the remaining four were in Group C.   It seems unlikely 
therefore from these observations that frequency of review is important in rate of 
catheter infection.   Although the numbers are very small in this study, there is no 
obvious difference in the incidence of any HPN-related complication between the 
three groups.  Venous thrombosis associated with the feeding line, mechanical failure 
and metabolic complications were all reported rarely.   For each of these 
complications, the patients involved were distributed between the three groups and no 
correlation was apparent between type of HPN-related complication and frequency of 
review.  
 
Ten patients were newly commenced and remained on HPN in Scotland for at least 
three consecutive months during 2006.   These ‘new’ patients were analysed 
separately for frequency of review and complication rates.   Two new patients had 
four documented HPN-related complications between them, one having repeated 
episodes of dehydration, the other a single proven catheter infection. 
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2.5 Discussion 
The British Artificial Nutrition Survey data shows that both point and period 
prevalence of patients prescribed HPN is increasing year on year, yet little is known 
regarding the adequacy of monitoring of these patients post-discharge from hospital. 
A European multi-HPN centre questionnaire-based study in 2006 concluded that 52% 
of patients were reviewed at 2-3 monthly intervals once stable with a degree of 
variation between one and twelve months.   Parameters monitored were based on local 
protocols and often measurements were taken on a ‘when clinically indicated’ basis 
(Wengler, Micklewright et al. 2006). 
 
In Scotland, the Home Parenteral Nutrition Managed Clinical Network aims to ensure 
the provision of standardised treatment across a large geographical area without the 
need to have to centralise treatment to large HPN centres. The MCN has been 
collecting clinical data on its patients for the past seven years and analysis of this aims 
to consolidate knowledge of Scottish HPN monitoring as a whole and between 
centres, ensuring a national guideline is followed and that this guideline is 
appropriate.   The results of treatment in this complete geographical community may 
be more realistic and true to life than those reported from tertiary referral centres. 
 
Wengler et al studied the monitoring practice of HPN across Europe and concluded 
that the majority of centres were similar to Scotland in having a monitoring interval 
for stable patients of 3 months, with a large degree of variation of between 1 and 12 
months.   In this study, patients discharged on HPN within the last 12 months were 
identified separately but no comment is made to the frequency of their review 
interval.   It seems that Scotland is in line with the rest of Europe regarding 
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monitoring frequency but Wengler et al make no comment on complication rates.   It 
is clear from the results of this study that in many cases the targets set by the Scottish 
HPN MCN are not being met and that a large proportion of patients are not regularly 
seen within the one-hundred day interval. 
 
There are undoubtedly more reviews that take place on an informal basis, and 
exceptions where patients are seen elsewhere by healthcare professionals, when 
patients attend for other clinics or contact the nutrition support team with specific 
queries.   One patient never attends HPN review but has routine bloods, vitamins and 
micronutrients checked when he attends his renal clinic appointments and 
consequently meets the target, in frequency if not in content of review.   Overall, it 
can be seen that Scottish patients receiving HPN are not monitored as often or as 
thoroughly as is recommended by our own guideline.   Most importantly, the nutrition 
support team varies in its skill mix between centres, some benefiting from a dietician 
and therefore monitoring anthropometry very successfully and others having a 
biochemist to oversee the bloods, vitamins and micronutrients.   One centre, with 
considerable experience in HPN therapy, has elected to monitor micronutrients and 
vitamins at six monthly intervals.   For these patients, they will appear to breach the 
recommended intervals for visits but remain very closely and conscientiously 
monitored.   From the centres questioned, it would appear that nutrition clinics do not 
run every week because this is impractical and therefore if an appointment is missed, 
it is entirely possible that review will not take place within the guideline of one 
hundred days as the next clinic will have already been scheduled for several weeks 
time. 
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The frequency of review was found to be inversely correlated with the duration of 
HPN treatment.   This might be expected when you consider that it would be 
instinctive to keep new patients under closer review than the more long-term and 
presumably stable patients.   However, if the guidelines are revisited, no real 
distinction is made between these two types of patients with regard to monitoring 
frequency.   All new patients were in Group A and the patients with the longest 
duration of treatment, sometimes many years on parenteral nutrition, tended to be 
found in Group C, where review frequency was never within one hundred days of the 
previous clinic appointment.   This was not exclusively the case, with some long term 
and presumably cautious or complicated patients reviewed frequently and some 
relative new comers managing to be seen far less often.   As is seen from the review 
of complications, no detrimental effect on complication rate was determined by less 
frequent review. 
 
Examining the content of the review appointments, it was encouraging that weight, 
arguably the simplest but most informative parameter, was the most frequently 
monitored of all the components with 86% of all clinic appointments recording this 
information.   Twenty reviews did not measure weight, and twelve of these were from 
one hospital, perhaps illustrating less robust methods of ensuring weight 
documentation or an active decision not to weigh all patients at all visits. 
 
The authors believe anthropometry to be an excellent and valuable method of 
monitoring nutrition status, eliminating concerns over fluid balance and providing a 
quantitative assessment, when used by experienced personnel to ensure 
reproducibility.   As a somatic measurement, it provides most information when 
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performed sequentially to monitor changes in nutritional status.  Anthropometry was 
infrequently monitored at all centres yet it and is not known whether this omission 
was due to a lack of training or equipment.   Thirty-four clinic appointments (24%) 
measured anthropometry, with 21 appointments (62%) of these originating from one 
hospital benefiting from a dietician being present at all HPN clinic reviews to perform 
the measurements.   Anthropometric data was very much an ‘all or nothing’ 
occurrence.   When measured at review clinics, all three measurements of TSF, MUC 
and MAC were usually recorded.   If a single measurement was made, at clinics not 
benefiting regularly from a dietician it was TSF that was infrequently recorded.   
Looking at new patients separately, anthropometry was measured at 21% of 
appointments.   This is a very similar figure to that of the whole group analysis and 
most likely represents similar problems of lack of training or facilities at these clinics.    
 
As stated in the ESPEN guidelines for HPN (Staun, Pironi et al. 2009) it is 
recommended that non-nutritional issues including psychological or social problems 
be monitored and addressed alongside the medical management of HPN patients.   
The authors recognise and acknowledge the importance of this aspect of continuing 
patient care.   Currently, within the MCN, patient well being, difficulties with 
equipment or feed and relevant issues of a psychosocial nature are recorded 
informally on the database within the clinic review/dietetics section.   These elements 
are under investigation by Baxter et al who have produced an HPN-specific quality of 
life questionnaire to enable routine collection of quality of life data.   In view of this 
pending paper, in part conducted and written by the Scottish HPN MCN manager, it 
was felt that these elements of review should not be addressed in this research paper.   
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In the future, it is hoped that the HPN-QOL become part of the routine clinical 
management of HPN patients (Baxter, Fayers et al. 2009). 
 
One hundred and thirty one of the total 141 clinic visits resulted in blood tests being 
taken.   The results shown in figure 2 indicate that when bloods are taken, urea and 
electrolytes, liver function tests and full blood counts are very successfully ordered, as 
would be expected of most follow up appointments.   It is of some concern that 
glucose and CRP were not assessed with the same frequency as both are universally 
available and yield valuable information in this group of patients.   HPN patients may 
develop impaired glucose tolerance or diabetes and CRP may alert nutrition teams to 
the presence of sub-clinical infection and is essential if one wishes to interpret the 
micronutrient levels appropriately.  
 
Vitamin B12 and folate require the filling of two further blood tubes and only half of 
all clinic appointments measured this component of the nutrition screen.   Glucose is 
also a separate tube to fill.   Clinic teams must specifically elect to request and send 
each of these tests as no predetermined check-list is currently utilised.   HPN patients 
are sometimes difficult to bleed, with chronic conditions leading to poor venous 
access.   Often the small amount of blood obtained must be prioritised for one test at 
the expense of another.   In these situations, and with these variables, choice of tests 
ordered may vary between centres and nutrition team members, resulting in a different 
spectrum of tests performed. 
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HPN patients are at higher risk of bone disease and mineral flux and as such calcium 
and vitamin D levels should be regularly monitored.   Calcium was measured in 72% 
of cases.   Vitamin D was requested on 28% of visits.   
 
The monitoring of vitamins, micronutrients and trace elements is an essential part of 
clinic reviews in HPN patients, as sub-clinical deficiencies in these substances can 
result in impairment of immune function and lead to an increased risk of developing a 
disease process such as infection, neoplastic disease or coronary artery disease 
(Shenkin 2001).   It is apparent from the results (figure 3) that vitamins and 
micronutrients are usually ordered as a batch or not at all, most having frequencies of 
between 48% and 60%.   The slight variation may be due to irregularities with 
processing at the laboratory stage.   Vitamin C in particular must reach the laboratory 
within four hours, or it becomes unsuitable for analysis.   Another exception is 
vitamin D, which, as mentioned above, is not part of a ‘micronutrient screen’ and 
therefore must be specifically requested.   The omission of Vitamin D renders the 
micronutrient screen incomplete in the majority of cases, however as noted above 
excluding this micronutrient leads to a more satisfactory rate of this aspect of 
monitoring.   It would be interesting to investigate the proportion of these assays that 
were abnormal, however this data set is incomplete. 
 
It is perhaps reasonable to expect that patients recently commenced on HPN may have 
a higher rate of complications than those on long term therapy.   These results would 
suggest that new patients do not incur vastly greater numbers of complications than 
stable patients; however, as all new patients were reviewed within the recommended 
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time period throughout the year, and therefore in Group A, we are unable to comment 
on the effect of the regularity of review.    
 
All 10 of the patients newly commenced on HPN during 2006 met the standard 
regarding monitoring frequency.   In only 75% of new patient visits were their 
weights documented.   This is somewhat surprising in view of the difficult fluid 
balance issues that often surround the commencement of parenteral nutrition.   The 
authors consider the measurement of weight to be helpful and informative as to 
whether, in the early days of treatment, patients are retaining fluid on HPN and more 
long term whether they are gaining and maintaining body mass.   In the subset of new 
patient results, one hundred percent of clinic appointments involved blood tests.   One 
hundred percent of patients had UE measured, 96% liver function tests and full blood 
count.   Unfortunately, there was no improvement in glucose monitoring despite these 
patients all being newly commenced on therapy, but CRP was more frequently 
monitored in 71% of reviews.   Within the new patient subset, micronutrient 
monitoring was very similar to the whole group findings, and was again largely an ‘all 
or nothing’ request.   In half of the new patients, micronutrients were tested but in 
only two cases were all nine recommended nutrients measured.   When sent, the 
majority of requests were for all micronutrient and vitamin levels except vitamin D.   
Interestingly, this group of patients had a much higher percentage of reviews 
measuring vitamin C.   This is difficult to explain, as it is not a parameter that is 
known to be particularly unstable on commencing HPN, nor is it commonly toxic and 
therefore there appears to be no reason for this increased surveillance of vitamin C 
levels in new HPN patients.   Perhaps it is the result of better logistics at this subset of 
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hospitals, where blood samples reach the laboratory more promptly, preserving the 
ability to measure vitamin C.   
 
To date, there is little evidence as to the consequences of various monitoring regimens 
for HPN patients.   The results of this study do not support an association between 
review interval and complication rate.   Most interestingly, similar numbers of 
patients in each group were found to have no reported complications, despite the 
different frequencies of supervision.   Looking at the patients reporting complications 
in the three groups compared with the patients reporting no complications, it was 
apparent that there was no significant relationship between frequency of review and 
HPN-related complication rate. 
 
The period of three months as a review frequency for the Scottish HPN MCN patients 
was set by experts in the field of parenteral nutrition, and approved by NHS Quality 
Improvement Scotland in 2003.   However, from the current study, there may be an 
argument for increasing the length of time between review appointments, without 
detrimental effect to patient safety.   It may be that nutrition support teams already 
employ a subconscious two tier system when monitoring their HPN patients, bringing 
back more unstable patients more frequently.   Similarly, patients themselves may be 
contributing to the apparent failure to meet set standards, electing to attend less 
frequently when well and with increased frequency when complications arise or 
following hospitalization.   Certainly, from this study the patients seen most often had 
the highest numbers of HPN-related complications.  Formalising this approach and 
tailoring review to patient needs may be appropriate.   There is considerable 
implication for resources, both financially and in clinical workload and a safe 
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reduction in the demands of supervision for these patients may be welcomed by those 
involved in funding and managing this expensive therapy. 
 
This study suggests areas which may be targeted for improvement.   The first is the 
multi professional nature of the review clinics.   It is clear that the absence of this 
team approach can lead to a less comprehensive appraisal of patient progress.   The 
difficulty with achieving this level of review is the high demand on staff for a 
relatively small group of patients.   It may be that more complete sets of blood results 
would be obtained if each hospital laboratory agreed a list of tests, which would be 
performed as an “HPN screen” so that there was no need to order the tests 
individually.   However, it is not possible to improve on the poor venous access of 
most of these long-term patients! 
 
The database contains many incomplete fields at present.   Undoubtedly a more 
complete data set, particularly the dietetics and outpatient review section of the 
database, would enable an alternative and perhaps clinically superior method of 
assessing the effectiveness of monitoring standards. 
 
Additionally, the Managed Clinical Network may benefit from the construction of a 
proforma to provide guidance on essential and desirable components for HPN review 
clinic appointments.   This may ensure that simple informative tests such as weight 
are more reliably documented and when small amounts of blood obtained, these are 
directed to the most clinically beneficial tests. 
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The current study therefore provides more information about current practice in 
Scotland, seemingly representative of Europe in its monitoring practice, and may 
serve to generate some much needed evidence base for future refinement of 
monitoring practice. 
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2.6 Tables and Figures 
 
Table 2.1 
The range of underlying diseases and indications for home parenteral nutrition, the 
frequency of monitoring and complications in patients receiving HPN in Scotland in 
2006 (continued on next page). 
Non-Standard Abbreviations: HPN - Home Parenteral Nutrition; NICE - National 
Institute for Health and Clinical Excellence; MCN - Managed Clinical Network 
 
  
HPN clinic 
review in 
2006 
  
Demographics 
always 
within 100 
days (A) 
inconsistentl
y within 100 
days (B) 
never within 
100 days (C) Totals 
all patients 16 19 18 53 
new patients 10 0 0 10 
age (mean) 49 55 55 ! 
sex M:F 7:9 6:13 7:11 ! 
     
Underlying disease     
crohn's disease 5 7 8 20 
motility disorder 2 2 3 7 
ischaemia 1 5 1 7 
malignancy 1 1 1 3 
radiation enteritis 2 1 0 3 
other 5 3 5 13 
     
Indication for HPN     
short gut 6 12 12 30 
obstruction 0 1 3 4 
fistula 0 1 0 1 
malabsorption 4 2 2 8 
other 5 3 1 9 
unknown 1 0 0 1 
     
Duration of HPN 
treatment (years)     
median (range) 0.65 (0.4-4.0) 4.3 (0.5-9.5) 7.0 (1.7-15.4) ! 
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Complications     
all complications 18 8 8 34 
total patients affected 5 6 5 16 
new patients affected 2 0 0 2 
pts with HPN-related 
complications 4 3 4 11 
pts with disease-
related complications 1 2 0 3 
pts with both types of 
complications 0 1 1 2 
pts with no 
complications 11 13 13 37 
     
HPN complications     
line infection 4 5 5 14 
thrombosis 1 1 0 2 
mechanical 0 1 1 2 
metabolic 3 3 1 7 
     
Pts with HPN related complications    
line infection 3 3 4 10 
thrombosis 1 1 0 2 
mechanical 0 1 1 2 
metabolic 1 1 1 3 
 
Table 2.1 (continued - page 2) 
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Figure 2.1 
The adequacy of HPN clinic reviews 
 
The Scottish MCN guideline recommends that an HPN clinic review include 
biochemical and haematological tests, vitamins and micronutrient level checks, 
weight measurement and anthropometry. 
Non-Standard Abbreviations: HPN - Home Parenteral Nutrition; MCN - Managed 
Clinical Network 
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Figure 2.2 
Performance of biochemical and haematological tests at HPN clinic reviews as 
per MCN guideline 
 
Abbreviations:   MCN - Managed Clinical Network, HPN - Home Parenteral 
Nutrition, UE - Urea and electrolytes, LFT - Liver function tests, Glu – Glucose, CRP 
- C reactive protein, Mg – Magnesium, Ca – Calcium, FBC - Full blood count, FERR 
- Ferritin 
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Figure 2.3 
Performance of vitamin and micronutrient measurement at HPN clinic reviews as per 
MCN guideline. 
 
Abbreviations:   MCN - Managed Clinical Network, HPN - Home Parenteral 
Nutrition, B1 - Vitamin B1, B2 - Vitamin B2, B6 - Vitamin B6, C - Vitamin C, D - 
Vitamin D, Mn – Manganese, Cu – Copper, Zn – Zinc, Se – Selenium, B12/FOL  -
Vitamin B12/Folate 
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Chapter 3 
Home Parenteral Nutrition in Scotland: Outcome and seven year 
prospective follow up in a nationwide population 
3.1 Introduction 
Home Parenteral Nutrition (HPN) plays a crucial and life-saving role in the treatment 
of patients with intestinal failure.   A variety of indications can necessitate parenteral 
feeding, most commonly short bowel syndrome, but also bowel obstruction, 
dysmotility, malabsorption or a combination of conditions.   Diagnoses include 
Crohn’s disease, ischaemic bowel, radiation enteritis, malignancy and abdominal 
trauma. 
 
In Scotland, an important opportunity is provided to review long term survival and 
HPN dependence across an entire population by the existence of the Scottish HPN 
Managed Clinical Network (MCN).   The network was formed in 2000 and since its 
creation has collected and recorded prospective data on all patients receiving HPN in 
Scotland. 
 
Survival data for HPN patients has been reported in multiple case series across the 
United Kingdom and Europe.   Data collected by the British Artificial Nutrition 
Survey demonstrate 92% one year survival of patients receiving HPN (Jones 2003).   
Five year survival of patients receiving HPN has been reported from North America 
and Europe as ranging from 60-79%. (Messing, Crenn et al. 1999; Vantini, Benini et 
al. 2004; Jeppesen, Staun et al. 1998; Scolapio, Fleming et al. 1999; Lloyd, Vega et al. 
2006; Pironi, Forbes et al. 2008; Lloyd, Zabron et al. 2008)  (25-29, 31, 57).  
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Previous studies have identified factors associated with prognosis to include residual 
small bowel length (Messing, Crenn et al. 1999), age at initiation of HPN (Vantini, 
Benini et al. 2004; Jeppesen, Staun et al. 1998), underlying primary diagnosis 
(Vantini, Benini et al. 2004; Jeppesen, Staun et al. 1998) and HPN dependency 
(Vantini, Benini et al. 2004). 
 
To date, studies have generally reported on either single centre experiences or those of 
tertiary referral centres where large numbers of highly selected intestinal failure 
patients are treated.   Through the existence of the MCN, we are able to report the 
survival rates and outcomes of HPN patients across the whole of Scotland, where 
treatment is delivered locally under nationally agreed guidelines by each hospital 
possessing an appropriately constituted Nutrition Team who are members of the 
Scottish HPN network.   As a result of the network and the consequent availability of 
HPN across this wide geographical area, we are provided with this diverse 
demographic to consider.   
 
This study aims to establish whether this population of patients behave in a similar 
way to previously reported groups in terms of survival, prognostic factors and HPN 
dependence.   Unusually, perhaps uniquely, all patients included in the study have 
been followed and their data entered prospectively since commencement of their 
parenteral nutrition. 
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3.2 Methods 
All patients receiving HPN funded by the NHS in Scotland are known to the MCN 
through ongoing contact between the established centres and the Network Manager. 
In addition there is constant publicity about the network to hospitals not involved, and 
there are regular reports from the commercial company providing the HPN service to 
the network.   This report includes all patients on HPN in Scotland from January 2000 
until the censor date of 31st December 2007.   
 
Data was collected from the purpose-built Microsoft Access database, completed 
prospectively by nutrition teams at all HPN MCN centres.  Missing or queried data 
were resolved by one of the researchers (NH) contacting the local nutrition team, and 
via case note review.   Data collected included age at commencement of HPN, gender, 
diagnosis and mechanism of intestinal failure necessitating HPN, duration on 
treatment (calculated from the date of discharge from hospital on HPN), patient 
mortality including cause of death and ongoing HPN dependence.   HPN dependence 
was taken as an ongoing requirement for parenteral nutrition for greater than two 
years following discharge, or until either death or withdrawal from HPN due to poor 
prognosis.   Reasons for stopping HPN treatment were also noted.   For the majority, 
this was death or treatment withdrawal for poor prognosis, or recovery / surgical 
intervention/bowel adaptation.   Several patients progressed to enteral nutrition, and in 
a small group, HPN was withdrawn for a miscellany of other reasons. 
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3.3 Statistical analysis 
All patients who commenced HPN prior to the formation of the MCN were excluded 
from the data, leaving an entire group of HPN patients with purely prospective results.   
All patients were followed up until 31st December 2007.   Minitab was used to analyse 
the outcome data.   Kaplan-Meier survival analysis was used to calculate the overall 
probability of survival and 1, 3 and 5 year survival rates.   Median survival time was 
also calculated.   Patients surviving until the censor date and remaining on HPN were 
then analysed, with respect to diagnosis using the Log Rank test.   The overall 
difference was calculated as was the difference between each pair of diagnoses. In 
addition, age at first discharge was analysed by plotting against date of first discharge.    
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3.4 Results 
The study covers the eight-year period from January 2000 to December 2007.   
Throughout the study period, 136 patients received HPN under the care of the Scottish 
MCN.   This equates to 17 new cases per year.   Duration of treatment totalled 271 
patient years and averaged 2 years, with a range of one month to 8 years.   The 
median age for new patients was 47 years, with a range of 16 to 80 years.   The 
commonest age range for new patients was 41 – 59 years, accounting for 53% of all 
new patients commenced on HPN therapy (Table 3.1).   Twenty one percent of 
patients were in the oldest age group. A single patient was referred to Hope Hospital 
Salford in 2003 and has been followed up there by his own preference.   He has only 
been referred for follow up in Scotland in 2010 and is therefore not included in our 
data set. 
 
Table 3.1 Demographic data for 136 HPN patients 
Characteristic Patients (%) 
Gender  
Male 
Female 
 
46 (34) 
90 (66) 
Age at start of HPN 
treatment 
<40 
41-59 
>60 
 
36 (26.5) 
72 (52.9) 
28 (20.6) 
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Table 3.2 Diagnoses within the study  
 
The commonest diagnosis amongst the patients was Crohn’s disease, accounting for 
34% of the group.   Twenty percent of patients had a diagnosis of ischaemic bowel 
disease and eight percent had a malignancy.   Four patients, accounting for 3%, had 
radiation enteritis and a quarter of all patients had a miscellany of ‘other’ diagnoses, 
including chronic pancreatitis, sclerosing peritonitis, post surgical complications, 
hypoganglionosis, and visceral hypersensitivity (Table 3.2).    
 
Differences in the distribution of patients with respect to age at which treatment 
started, the duration of treatment and when in the study they commenced HPN were 
assessed and are summarised in Figures 3.1, 3.2 and 3.3. 
 
In Figure 3.1, age at initiation of HPN was plotted with respect to diagnosis.   Each 
pair of diagnoses were compared using a t-test; Table 3.3 shows the resulting p-
values.   Patients with Crohns disease were significantly younger at time of initiation 
of HPN than patients with ischaemia or ‘other’ diagnoses.   Patients with ischaemia 
were also significantly older than those with motility disorders and ‘other’ diagnoses. 
Diagnosis Patients (%) 
Crohn’s 46 (34) 
Ischaemic Bowel 27 (20) 
Malignancy 11 (8) 
Motility 13 (10) 
Radiation Enteritis 4 (3) 
Other 35 (25) 
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Table 3.3   Age at diagnosis. Comparison between disease groups (p values). t-test 
START AGE Ischaemia Motility Malignancy Other 
Crohns <0.001 ** 0.190 0.036 0.006 * 
Ischaemia  0.010 * 0.646 0.047 * 
Motility   0.199 0.285 
Malignancy    0.499 
 
Figure 3.3 shows the distribution of duration of treatment with respect to diagnosis.   
A Mann Whitney u test was used to test pairs of diagnoses for significance as this data 
set is non-parametric.   Table 3.4 shows resulting p values.   The only significant 
difference observed in this group was seen on comparison of patients with ischaemia 
and those with motility disorders, with the ischaemia group having a shorter duration 
of treatment. 
 
Table 3.4   Duration of Treatment. Comparison between disease groups (p values). 
Mann-Whitney test 
DURATION Ischaemia Motility Malignancy Other 
Crohns 0.554 0.056 0.729 0.329 
Ischaemia  0.027 * 0.949 0.985 
Motility   0.093 0.019 
Malignancy    0.920 
 
In Figure 3.3, the patient groups were plotted with respect to date of commencing 
HPN to evaluate indications for treatment over the study period.   A t-test was used to 
examine significance (Table 3.5).   Patients with ‘other’ diagnoses commenced HPN 
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significantly later within the study period than patients with malignancy.   No other 
significant differences were observed between groups. 
 
Table 3.5   HPN start date. Comparison between disease groups (p values). t-test 
START DATE Ischaemia Motility Malignancy Other 
Crohns 0.711 0.293 0.138 0.233 
Ischaemia  0.441 0.266 0.155 
Motility   0.887 0.086 
Malignancy    0.023 * 
 
Table 3.6   Indications for HPN within this study 
Indication for HPN Patients (%) 
Obstruction 7 (5) 
Short gut 74 (54) 
Malabsorption 10 (7) 
Fistula 14 (10) 
Malnutrition 2 (2) 
Gastric hold up 1 (1) 
Sclerosing peritonitis 1 (1) 
Other 27 (20) 
 
Over half of all patients (54%) had a short gut as their indication for HPN.   Other 
indications included obstruction, malabsorption, fistulae, malnutrition, gastric hold up, 
sclerosing peritonitis and a collection of more obscure reasons, labelled ‘other’ which 
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included protein losing enteropathy, visceral myopathy and oesophageal dysfunction 
(Table 3.6). 
 
Of the 136 patients in the group, forty seven patients (35%) were still receiving HPN 
on the censor date of 31st December 2007.   Thirty four patients (25%) had died and 
fifty five patients (40%) had stopped receiving HPN for reasons other than death, no 
longer requiring the therapy.   These reasons included recovery (51%), bowel 
adaptation (22%), surgical intervention (25%) such as bowel re-anastomosis or 
closure of fistulae and one patient who stopped for undocumented reasons (2%). 
 
Figure 3.4 shows the outcome of all patients at the censor date.   Figure 3.5 shows the 
break down of reasons for discontinuing HPN treatment in those patients labelled 
‘stopped HPN’ in Figure 3.4.   Half of these patients recovered, were weaned 
successfully and no longer needed parenteral nutrition, one quarter had 
gastrointestinal surgery, 22% underwent bowel adaptation, and a small percentage had 
other reasons for termination of treatment.  All patients in this group stopped HPN to 
reinstate enteral nutrition.    
 
3.4.1 Mortality 
There were a total of 34 deaths in the study group.   These are detailed in Table 3.7.   
The majority, twenty two patients (65%) who died during the study period had disease 
related causes of death.   Only four patients (12%) had pure HPN related deaths and a 
further two patients (6%) had deaths attributed to a combination of disease and HPN.   
HPN related deaths were due to either sepsis or liver disease. 
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Table 3.7   Cause of death of patients on HPN 
Cause of death Patients Median months on HPN  
HPN related 4 4.5 
Disease related 22 10.5 
Combination 2 17.5 
Other 5 7 
Unknown 1 25 
 
‘Other’ includes; 
• metastatic breast cancer 
• sepsis 
• lung cancer 
• myocardial infarction 
• acute myeloid leukaemia 
 
Fifty five patients had stopped HPN due to reasons other than death (Table 3.8). 
 
Table 3.8   Reasons for stopping HPN 
Reason Patients Median months on HPN  
Recovered 28   8 
Surgery 14   5.5 
Bowel adaptation 12 12.5 
Other 1   4 
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Other includes one patient with co-morbidities, multiple line infections and a mutual 
decision between HPN team and patient not to continue HPN. 
 
3.4.2 Survival analysis 
The overall survival probability after starting HPN for the 136 patients studied was 
86.0% at 1 year, 81.6% at 2 years, 78.7% at 3 years, 77.2% at 5 years and 76.5% at 6 
years (Figure 3.6). 
 
For Figure 3.7, patients who stopped HPN for reasons other than death have been 
removed.   The plot shows survival in those who died on HPN and those who were 
still receiving HPN at the censor date.   This gives the survival plot for all patients 
who during the study period died on HPN or continued it until the end of the study. 
 
Survival distribution by diagnosis is shown in Figure 3.8.   Log rank test showed the 
overall differences in survival to be significant at p<0.001.   P<0.05 was taken as 
significant.   Probability of survival was therefore influenced by disease diagnosis.   
Table 3.9 shows the p values for each pair of diagnoses.   Significant differences were 
found between Crohn’s disease and ischaemia, ischaemia and motility disorder and 
ischaemia and ‘other’ diagnoses.  A highly significant difference was found between 
survival in Crohn’s disease and malignancy, motility disorder and malignancy and 
malignancy and ‘other’ diagnoses. 
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Table 3.9   All patients: Survival grouped by disease - Log-Rank comparisons 
between groups 
 Ischaemia Motility Malignancy Other 
Crohn’s 0.009 * 0.136 0.001 ** 0.910 
Ischaemia  0.006 * 0.295 0.011 * 
Motility   0.001 ** 0.121 
Malignancy    0.001 ** 
 
Survival was assessed with respect to age at initiation of treatment (Figure 3.9).   
Patients were grouped into those who started HPN aged <40yrs (n=36), 40-59yrs 
(n=72) and >60yrs (n=28) and survival at 5 years was calculated for each group.   The 
overall log rank p value is 0.957.   Five year survival for each group is 82.7, 76.0 and 
74.1 % for the three groups respectively. 
 
Figure 3.10 plots the survival of the HPN patients by their time of starting treatment.   
The 136 patients have been divided into Group 0, those commencing HPN 2003-
2005, Group 1, who commenced treatment in 2000-2002, and Group 2, for patients 
starting treatment on or after 2005.   Log rank comparisons of each pair of groups 
show no significant difference between starting HPN in any of the three time periods 
(Table 3.10). 
Table 3.10   Survival grouped by time starting HPN.  P=0.537 Log-Rank comparisons 
between groups 
 Group 1 Group 2 
Group 0 0.671 0.502 
Group 1  0.262 
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Patients from the two centres providing HPN to the largest numbers of patients in 
Scotland were extracted and their survival plotted against patients from all other 
Scottish centres.   There was no difference between these two groups p=0.518 (Figure 
3.11). 
 
3.4.3 Home Parenteral Nutrition dependence analysis 
In this study dependence on HPN was 61%, 51% and 48% at 1, 3 and 5 years (Figure 
3.12). 
Additionally, 49 cases (89%) of the 55 cases where PN was weaned successfully 
happened within two years of commencing therapy.   Of the 44 patients not weaned 
off HPN within 2 years, only a subsequent 6 patients (14%) were successfully weaned 
from HPN to other forms of nutrition and 86% were classified as having permanent 
intestinal failure.   Of the six patients who managed to stop HPN after more than 24 
months of therapy, 4 were classified as having undergone bowel adaptations and 2 as 
recovered from the cause of intestinal failure. 
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3.5 Discussion 
The Scottish Managed Clinical Network oversees the care of all patients in Scotland 
who are receiving Home Parenteral Nutrition.   This arrangement provides a unique 
opportunity to follow the outcome of a geographically diverse and complete HPN 
population over a number of years.   Data collection in this study is entirely 
prospective.   The MCN was set up in 2000 and all patients commenced on HPN prior 
to this have been removed from the study.   Patients starting treatment from this time 
onwards have been included to ensure demographic and clinical data is accurate and 
reliable. 
 
3.5.1 Patient demographics 
As in the national data, there is a trend for new patients to be in the older age group of 
60+ years (Jones 2007; Elia, Russell et al. 2001).   The age distribution of patients 
reflects that of the national data, with the commonest age range for new patients being 
41-59 years.   Patient demographics and diagnoses were similar to previous studies 
with the exception of the percentage of patients receiving HPN for malignancy, which 
is far fewer in this Scottish study and the UK in general when compared with patient 
prescriptions for HPN in North America (Scolapio, Fleming et al. 1999).   
Additionally, no patients in this current study were given HPN for an HIV-related 
disorder, illustrating a geographical difference in practice. 
 
3.5.2 Underlying disease processes 
The most common diagnosis leading to the prescription of HPN was Crohn’s disease, 
(34%), followed by ischaemic bowel (20%).   This is comparable with the British 
Artificial Nutrition Survey (BANS) data (Jones 2007).   Also consistent with the 
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BANS report (Jones 2007) is the miscellany of ‘other’ diagnoses which make up a 
large proportion of HPN patients in both studies.   This is thought to be due to a 
heterogenous group of diagnoses - mainly surgical complications - necessitating 
parenteral nutrition, but could also be due to inconsistencies in classifying patients’ 
diagnoses on the database.   Worldwide there are differences in the use of HPN.   
Inflammatory bowel disease is a much less common indication for HPN prescription 
in other parts of the world, with 11% of patients in North America (North American 
Home Parenteral and Enteral Nutrition Registry 1994 1992), and a minor percentage 
of all HPN cases throughout Asia (Wang, Wu et al. 2007).   In mainland Europe, the 
United States, and Asia a far greater proportion of HPN patients have a cancer 
diagnosis than in the UK.   Italian nutrition teams prescribe 88% of their HPN for 
malignancy (Violante, Alfonsi et al. 2006).   In America, 42% of HPN is for cancer 
patients (North American Home Parenteral and Enteral Nutrition Registry 1994 
1992), in Japan the proportion is 40% 93 and in Taiwan it is over 70% (Wang, Wu et 
al. 2007).   In Scotland, this study finds only 8% of HPN prescription to be for 
patients with a primary diagnosis of malignancy.   Evidently, there remains much 
controversy and a lack of agreement internationally regarding the prescription of 
HPN.   This disparity presumably reflect large national differences in philosophic and 
economic viewpoints.   The management of patients with malignancy in the UK rarely 
includes the use of parenteral nutrition.   The insurance funded medical care in the 
USA may influence the numbers of cancer patients treated with this high maintenance 
therapy.   Previous work shows cancer patients to have similar readmissions for HPN 
related complications but four times as many for disease related ones (Howard 1992). 
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Italian studies deem HPN in terminal cancer patients to be a safe and effective 
treatment (Violante, Alfonsi et al. 2006).   Across Europe opinions are divided and the 
questions remain as to whether nutritional support improves the survival of patients 
with cancer or allows the patient to feel better and have an improved quality of life?’ 
(Bozzetti 1995).   Cancer patients with a diagnosis of malignancy generally fall into 
three broad groups; those with the iatrogenic malnutrition as a consequence of 
treatment of cancer, those with active cancer whose treatment is hindered by disease 
related malnutrition and those in the terminal phase with concurrent intestinal failure.   
It is with the terminal diagnosis of malignancy that most controversy remains and 
utilisation of this provision varies most from country to country.   HPN appears to be 
a valid intervention in terminal patients whereby death would be secondary to 
malnutrition rather than the spread of malignant disease.   It is obviously ethically 
unacceptable to randomise patients to either starvation or non-starvation and as such 
no quantitative data is available to strengthen arguments for the use of HPN in 
terminal patients.   Quality of life data would support HPN use with the aim of 
prolonging functionality as long as individual patient specific endpoints are identified 
to determine whether or not goals are accomplished and therefore whether to 
withdraw treatment. 
 
Demographic data were studied to investigate any temporal relationships or 
differences between diagnosis groups.   Over the years, there has been a broadening of 
the age range of patients starting HPN.   Only two categories of diagnoses contained 
patients that started their treatment before the age of thirty.   As would be expected, 
most young patients using HPN had a diagnosis of Crohn’s disease, where 
complications requiring parenteral nutrition can occur at any time.   One patient 
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commenced HPN just before his sixteenth birthday having developed small bowel 
fistulae to an ileostomy.   The rest of the patients who started HPN relatively young 
were in the ‘other’ diagnosis group, with diagnoses ranging from Systemic Lupus 
Erythematosis with gastric hold up, to chronic pancreatitis and chronic pseudo-
obstruction.   In the older age range at which patients were given HPN, ischaemic 
bowel and malignancy featured most commonly, although a single Crohn’s patient 
commenced treatment in his seventieth year and motility disorders and ‘other’ 
diagnoses also had patients of this age group beginning their therapy. 
  
Comparing pairs of diseases, Crohn’s disease was found to be significantly different 
to ischaemic bowel p<0.01, to malignancy p=0.036 and to the other diagnosis group, 
p=0.006 with respect to age of commencing therapy.   Ischaemic bowel was also 
significantly different to motility disorder, p=0.01 and other diagnosis, p=0.047 
groups.   This has been examined in previous studies.   Howard et al 1995 (Howard, 
Ament et al. 1995) looked at outcome in HPN patients in North America.   Diagnostic 
groups of Crohn’s disease, ischaemic bowel and motility disorders were pooled and 
outcome compared in paediatric, middle age and geriatric groups, concluding that 
although outcome was better in the younger age group over several outcome 
measures, including nutrition status at one year, complication rate and rehabilitation 
status, it was good in all three groups and age per se should not prevent patients 
receiving treatment.   Co-morbidities and simply older age may affect survival.   The 
diagnosis of ischaemic bowel occurs mainly in the older age group and has a 
somewhat poorer survival so consequently often results in a shorter duration of 
treatment.   But old age alone does not preclude treatment.   Younger patients had 
better survival rates on therapy, a greater likelihood of resuming full oral nutrition 
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after 1 year, and more complete rehabilitation than older patients. The only negative 
factor for paediatric patients was their more frequent readmission for HPN-related 
sepsis compared with adult subjects. Geriatric adults receiving HPN did not 
experience more therapy related complications than their middle-aged counterparts 
(Howard, Ament et al. 1995).   Perhaps it could be speculated that older age patients 
commenced on HPN would be more highly selected than disease equivalent younger 
patients. 
 
3.5.3 Duration of HPN treatment 
Figure 3.2 concerns duration of treatment and showed the majority of patients to be 
receiving relatively short term treatment with HPN i.e. 12-18 months for all diagnoses 
except motility disorder, for which patients duration of treatment was more varied - 
some with only a year or 2 of treatment and an approximately equal number receiving 
6, 7 or 8 years of treatment.   Overall, this probably relates to the nature of the 
disorder, with acute Crohn’s exacerbations, fistulae, or the short term treatment of 
malignant sequelae requiring spells of intravenous feeding, as compared to disorders 
of bowel motility, which are usually non-rectifiable requiring long term parenteral 
nutrition more frequently.   Ischaemia was significantly different in its duration of 
treatment to that of motility disorders.   This probably relates to the other 
cardiovascular complications which often accompany a patient with this diagnosis. 
 
3.5.4 Diseases treated with HPN over the study period 
Diagnoses were plotted with respect to time from beginning of study to examine any 
changing practice over the eight years (Figure 3.3).   The range of diagnoses for which 
HPN is given has not altered significantly in the last eight years in Scotland.   This is 
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comparable to United Kingdom data from the BANS report which compares 2000 and 
2006 new registrations, and point prevalence (Jones 2007).   In both the current 
Scottish study and the UK wide data, Crohn’s disease remains the predominant 
diagnosis (Jones 2007).   The number of ‘other diagnoses’ is on the increase in more 
recent years, with a cluster of new ‘other diagnoses’ commenced on treatment in the 
last 4 years in the current study.   This agrees with the BANS data (Jones 2007), and 
in both studies probably reflects an increasing number of patients who experience 
complications in complex surgical cases where the temporary or permanent outcome 
is a requirement for parenteral nutrition. 
 
3.5.5 Indications for treatment 
The principal indication for HPN in this study was short bowel syndrome (SBS) as 
was the case in previous studies (Messing, Crenn et al. 1999, Vantini, Benini et al. 
2004; Lloyd, Vega et al. 2006).   SBS usually results from repeated resection of small 
bowel strictures due to Crohn’s disease but can also result from extensive small bowel 
resection as a consequence of superior mesenteric artery / vein thrombosis or volvulus 
(Lal, Teubner et al. 2006; Irving 2000).   A UK based study showed that the cause of 
intestinal failure in the majority of their patients with Crohn’s disease was multiple 
unplanned laparotomies and that a far smaller percentage of Crohn’s disease patients 
acquired short bowel syndrome through either extensive disease or uncomplicated 
sequential resections (Agwunobi, Carlson et al. 2001).   Other indications included 
bowel obstruction, small bowel fistulae and malabsorption.   Bowel obstruction is 
often secondary to malignancy, which is an infrequent indication for parenteral 
nutrition in Scotland (5% in this study) yet is the commonest indication for HPN in 
Italy (Buchman, Moukarzel et al. 1994) and North America (North American Home 
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Parenteral and Enteral Nutrition Registry 1994 1992).   Differences in indications or 
diagnoses between centres and countries will inevitably have implications when 
survival data is interpreted.   Of note, no patients in this current study had an 
underlying diagnosis of AIDS, which mirrors the pattern of decline in the prescription 
of HPN for this disease in all countries except Belgium, where 35% of patients at one 
centre had AIDS as their underlying disease (Van Gossum, Bakker et al. 1999). 
 
3.5.6 Mortality 
There were a total of 34 deaths in the study group.   These are detailed in Table 3.7.   
The majority, twenty two patients (65%) who died during the study period had disease 
related causes of death.   Only four patients (12%) had pure HPN related deaths and a 
further two patients (6%) had deaths attributed to a combination of disease and HPN.   
HPN related deaths were due to either sepsis or liver disease. 
 
Death was as a consequence of disease in the majority of patients in the current study.   
Details on the HPN MCN database surrounding individual patient deaths are vague 
and in the majority a single drop down menu choice is applied for cause of death.   It 
is known that both HPN related liver disease and HPN related sepsis were causative in 
the death of four patients in this study.   Patients dying of disease related 
complications had a longer median duration of HPN therapy than those with HPN 
related deaths.   It could be postulated therefore that in the short term, death is more 
likely a consequence of HPN related problems but as a patient continues on therapy, 
their cause of death is much more likely to be attributable to their underlying disease 
process.  
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3.5.7 Outcomes 
Overall, the outcomes for the study population at the censor date was death in 25% of 
patients, whilst 35% of patients remained on HPN treatment and 40% stopped HPN 
due to improvement of condition or surgical intervention (Figure 3.4).   The group of 
patients who stopped HPN are represented in Figure 3.5.   Looking specifically at the 
patients who were able to stop HPN, 51 percent of this group recovered sufficiently 
from conditions where temporary HPN was required, either to rest the bowel, allow 
for fistulae healing or combat malnutrition.   Twenty-one percent underwent bowel 
adaptation, whereby their remaining gut adjusted to perform all necessary roles and 
thereby remove the need for parenteral nutrition.   One quarter of all patients who 
managed to stop intravenous feeding had surgical intervention to re-anastomose the 
bowel.   The literature does not contain many comparisons for this data, although a 
retrospective Italian study in 2002 found 51% of patients to still require HPN 
treatment at the end of analysis, 25% of patients were dead and 12.5% were 
successfully weaned from HPN.   A single patient underwent intestinal transplantation 
and a further 3 patients (7.5%) were followed by other centres (Pironi, Paganelli et al. 
2003). 
 
Survival probabilities throughout the follow up period are comparable with previous 
studies.   The 5 year survival probability of 77.2% may be compared with those of 
73% (Lloyd, Vega et al. 2006), 75% (Messing, Crenn et al. 1999) and 78.6% (Vantini, 
Benini et al. 2004).   The studies included in table 3.11 include two non-malignant 
populations, (Messing, Crenn et al. 1999 and Pironi, Paganelli et al. 2003).   Despite 
many European studies reporting malignancy as a common diagnosis treated with 
HPN, table 3.11 lists studies in which there is minimal representation of this 
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behaviour.   The UK study (Lloyd, Vega et al. 2006) and the current Scotland study 
both include patients with malignancy but local practices keep these numbers low.   
On this basis, it is therefore not valid to surmise that HPN positively influences 
survival in malignancy. 
 
Table 3.11   Comparison of the survival probabilities throughout follow up within the 
literature, including the current study (Scotland) 
 1 yr 2 yr 3 yr 5 yr 6 yr 10 yr 
(Lloyd, Vega et 
al. 2006) 86%  77% 73%  71% 
(Pironi, 
Paganelli et al. 
2003)* 
97%  82% 67%   
(Vantini, Benini 
et al. 2004) 95% 93% 88% 79%  65% 
(Messing, Crenn 
et al. 1999)* 94%  86% 75%  60% 
Scotland 86% 82% 79% 77% 77% - 
* = non malignant study group 
 
When considering survival data the influence of the underlying disease must be 
recognized.   Different case series are likely to be influenced by the differences in the 
patient groups studied, and by whether or not the case series contains patients with a 
diagnosis of malignancy.   The closest comparison study in terms of study size and 
case mix in the literature shows very similar overall survival rates at 1, 3 and 5 years 
(Lloyd, Vega et al. 2006).   Differences in survival are apparent when diagnosis 
groups are compared.   Kaplan-Meier analysis shows significantly lower survival in 
subjects with malignancy and gut ischaemia when compared with the other groups of 
motility disorders, Crohn’s disease and other diagnoses (Table 3.12).   There are no 
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significant differences in survival between motility disorders, Crohn’s disease and 
other diagnoses, or between malignancy and gut ischaemia. 
 
Table 3.12   Probability of survival (Kaplan-Meier) by disease indication 
 Yr 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr 6 
Motility 100 100 100 100 100 100 
Other 90.2 85.4 85.4 85.4 85.4 85.4 
Crohn’s 92.7 88.6 86.3 86.3 86.3 86.3 
Ischaemia 74.1 66.6 62.9 55.5 55.5 55.5 
Malignancy 72.7 54.5 54.5 45.5 45.5 36.4 
 
Underlying disease was associated with probability of survival in this study.   As 
would be expected, subjects with Crohn’s disease had a better prognosis than those 
with ischaemia or malignancy (Table 3.13).   The estimated 5 year survival  (86.3% 
95% C.I. 73.3-96.5%) results are comparable with similar studies - 87% C.I 74-94% 
29, 75% C.I. 67-83% 25, 92% 28. 
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Table 3.13   Probability of survival (Kaplan-Meier) by disease indication at 5 years 
with 95% confidence intervals 
 
 
 
Predictably, survival was poor in patients with underlying malignancy, with all but 
one patients who died having disease related deaths.   Survival was also poorer in 
patients with bowel ischaemia, although for a disease renowned for its poor prognosis, 
perhaps 55% survival at five years is reasonably encouraging.   This diagnosis 
comprises both venous and the more common arterial disease.   The frequency of 
clinical manifestations of atherosclerosis in Great Britain - and the West of Scotland 
in particular - is especially high.   Our patient group is likely to contain a high 
proportion of patients with marked atheromatous disease, leading to arterial bowel 
infarction and a worse prognosis, as has been seen in previous studies (Messing, 
Crenn et al. 1999; Scolapio, Fleming et al. 1999).   Lloyd et al quoted a  better 
prognosis with ischaemic bowel patients and attributes this to a higher percentage of 
patients having venous pathology (Lloyd, Vega et al. 2006).   Motility disorders had a 
100% five year survival in this current study, but by comparison, in the study by 
Lloyd et al 2006 (Lloyd, Vega et al. 2006), survival was much worse in this group, 
approximately 55%.   A possible explanation might be the variation in the 
classification of patients into disease groups between studies.   The current study 
 Yr 5 95% CI 
Motility 100  
Other 85.4 74.5 – 96.1 
Crohn’s 86.3 73.3 – 96.5 
Ischaemia 55.5 36.3 – 74.3 
Malignancy 45.5 16.0 – 74.8 
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classified systemic sclerosis into a group of ‘other’ diagnoses, whereas the Lloyd 
study (Lloyd, Vega et al. 2006) categorises these patients as dysmotility disorder, 
consequently worsening survival statistics in this group. 
 
Little is found in the literature to address whether patients commenced on treatment 
earlier in the study period have differing survival rates to those who started treatment 
at a later date.   The current study found that survival during this relatively short time 
period was similar regardless of when therapy was commenced.   Similarly, but over a 
longer study duration, a previous study found that the decade of commencing HPN 
did not affect survival (Lloyd, Vega et al. 2006).   It is likely that the three time 
periods are not sufficiently chronologically distinct to show any differences in 
outcome dependent on date of commencement, however it is also possible that 
survival probabilities have plateaued until further treatment developments are made. 
 
Unlike previous studies (Messing, Crenn et al. 1999; Vantini, Benini et al. 2004; 
Scolapio, Fleming et al. 1999; Pironi, Paganelli et al. 2003) a younger age at initiation 
of HPN in this study did not show a significant survival advantage.   Jeppesen et al 
showed mortality was twice as high in patients aged over 50yrs (34%) as in younger 
patients (18%) (Jeppesen, Staun et al. 1998).   Lloyd et al found a significant 
relationship between patient age at commencement of HPN and survival, with an 
almost threefold risk of death in patients starting HPN at >55yrs compared with those 
starting at <54yrs (Lloyd, Vega et al. 2006).   It may not be valid to draw too many 
conclusions from the current study as our group numbers in both the under forty and 
over sixty years were small in comparison with previous reports.   However, the 
similarity of our survival data for all three age groups was striking (p=0.957).   
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Possible explanations may include a population with less severe disease or less co-
morbidity.   Additionally, the current study has a low proportion of cancer diagnoses - 
a disease more common later in life and a likely explanation for poor survival in these 
older age groups if high numbers of malignancy diagnoses are present.   This does not 
however account for differences from the Lloyd study which also contains relatively 
few cancer patients. 
 
The two centres who oversee the largest numbers of HPN patients in Scotland are 
Glasgow Royal Infirmary and Ninewells Hospital, Dundee.   Both have patients with 
more than ten years of HPN treatment.   Treatment with HPN in Scotland is facilitated 
through the Managed Clinical Network; it is not the intention to centralise care but to 
allow treatment to be delivered in the nearest hospital via adoption of national 
standards, guidelines and protocols (Scottish Home Parenteral Nutrition Managed 
Clinical Network ).   This allows equity of access and standardised treatment across a 
challenging geographical area.   Survival at these two large centres was compared 
with the combined outcome for all other Scottish centres.   Reassuringly, there was no 
difference in survival between these two groups (p=0.518).   This adds weight to an 
already strong argument for managing patients with a multi professional team 
approach and provides support to the existence of this Network, suggesting patient 
outcome is similar regardless of location within Scotland. 
 
3.5.8 HPN dependence 
Dependence on parenteral nutrition was calculated and compared with previous 
reported figures (Table 3.14).   HPN dependence in this study was broadly 
comparable to that of a French study which is entirely comprised of consecutive non-
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malignant adult short bowel patients from two centres monitored by an official 
regional HPN centre (Messing, Crenn et al. 1999).   This is a similar set up to the 
current Scottish study, with comparable monitoring and patient demographics.   In 
contrast, the strikingly different proportions of patients remaining HPN dependent in 
the Lloyd study (Lloyd, Vega et al. 2006) probably reflects the selection of complex 
patients referred to a tertiary centre. 
 
Table 3.14   HPN dependence 
 1 2 3 5 
Messing et al 1999 * 53% 49% - 45% 
Lloyd et al 2006 89% - 87% 84% 
Jeppesen et al 1998 - - - 75% 
Scotland  61% 53% 51% 48% 
* = non malignant short bowel syndrome group 
 
In the current study, 89% of patients with transient intestinal failure (IF) were weaned 
from HPN after 24 months, and a 86% of patients with greater than 24 months 
treatment went on to be classified as having permanent IF.   In the previous study by 
Lloyd et al (Lloyd, Vega et al. 2006), the equivalent figures were 95% and 94% 
respectively.   One explanation for our patients not stopping HPN as early as in 
previous similar studies may be that when patients are doing well clinically they may 
miss clinic appointments, or are reviewed slightly less often than patients with more 
clinical need.   This may delay the decision to attempt weaning until beyond the 24-
month point.   Of the patients who successfully weaned from HPN after more than 24 
months, half (3 patients) had a diagnosis of Crohns disease, and consequent short 
bowel syndrome.   These patients took an average of 43 months to achieve adequate 
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bowel adaptation, supporting suggestions that adult bowel adaptation can occur after 
1-3 years of HPN (Nightingale, Lennard-Jones et al. 1992). 
 
The first monoclonal antibody treatment for Crohns disease was introduced just prior 
to the start of the current study and this method of treatment may well have influenced 
outcome data specifically related to HPN patients with a diagnosis of Crohns disease.   
The successful treatment of recurrent and fistulating Crohns disease patients using 
Infliximab, Adalimumab or equivalents has undoubtedly enabled patients who 
previously would have remained parenterally fed to return to an enteral route of 
nutrition through these efficacious new therapies (van Deventer 1999).   More 
recently, the CHARM study (Crohn’s Trial of the fully human antibody adalimumab 
for remission maintenance) examined the efficacy of adalimimab for long-term 
maintenance in remission Crohn’s disease and concluded that adalimumab had a 
significantly lower rate of hospitalisation and surgery at one year than placebo 
(Feagan, Panaccione et al 2008).   Anti TNF therapies have also been found to be 
effective in the treatment of severe active Crohns disease (CLASSIC-I trial) (Hanauer, 
Sandborn 2006).   These developments may result in fewer patients acquiring short 
bowel syndrome secondary to surgical intervention and lessen the need for HPN in 
future years. 
 
 
3.5.9 Conclusions 
In conclusion, the five year survival of patients receiving HPN in this study was 
77.2%.   This equals the five year survival in the Lloyd study (Lloyd, Vega et al. 
2006), which centred on a tertiary referral centre for intestinal failure.   However, the 
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current study is an entirely prospective study, lending additional weight to the quality 
and reliability of data.   It also provides interesting information on how a complete 
geographical population receiving HPN behaves.   Age was not found to be predictive 
of survival in our study, and this may just be that our numbers were too small to show 
any differences. 
 
This study aimed to encompass all patients receiving HPN Scotland wide.   Towards 
the end of the analysis period a single patient who resides in Scotland but chooses to 
receive HPN monitoring from an English IF centre was located.   As he has never 
featured in our monitoring process, and is not counted in our survival statistics, we are 
able to accept and except him from this study and still draw conclusions on a 
population.   However, this development illustrates the difficulties in ensuring a whole 
population data is captured for analysis.  
 
HPN dependence in this study mirrored that of a French study, with just under half of 
all patients still dependent on HPN at five years.   Much higher percentages of 
patients remain HPN dependent in other recent studies, the reason for this is unclear 
but probably relates to the mix of patients involved, their range of underlying diseases 
and complexity of their cases.   It is also worth considering how a patient is deemed 
HPN independent, and whether it is more frequent reviews or smaller numbers at 
individual centres which provoke the nutrition team to contemplate whether a patient 
is ready or able to be weaned from treatment. 
 
Also encouraging for our Managed Clinical Network is the lack of survival difference 
between the two largest bases for HPN monitoring (Glasgow Royal Infirmary and 
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Ninewells Hospital Dundee) versus the rest of the nutrition centres across Scotland.   
It is certainly the intention of the Network to provide an equivalent service to all HPN 
patients irrespective of geographical location and this result supports an achievement 
of this and a obligation to continue with this essential supervision of therapy. 
 
Finally, and with a view to future work, a study is only as good as the data entered 
and in retrospect, some aspects of the Scottish HPN MCN database, from which all 
data has been gathered may benefit from improvement.   Accuracy is obviously a 
priority when compiling outcome date.   Drop down menus and free text boxes leave 
room for error and interpretation regarding such information as reason for stopping 
HPN and cause of death.   Additionally, many patients have either a diagnosis or 
indication for HPN listed as ‘other’.   Although this is sometimes necessary in 
individualised complex surgical cases, addressing this issue by either educating the 
persons responsible for data input or completion of a formal proforma at the time of 
commencing treatment with HPN may reduce this ‘other’ category and further 
improve data accuracy. 
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Figure 3.1 
Age at Initiation of HPN by diagnosis.   Grey dots represent individuals.   Blue cross 
represents mean.   Error bars 95% CI for the Mean 
n=136 
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Figure 3.2 
Duration of HPN treatment by diagnosis.   Grey dots represent individuals.   Blue 
cross represents mean.   Error bars 95% CI for the Mean 
n=136 
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Figure 3.3 
HPN starting date by disease.   Grey dots represent individuals.   Blue cross represents 
mean.   Error bars 95% CI for the Mean 
n=136 
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Figure 3.4 
Outcome at censor date 
n=136 
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Figure 3.5 
The break down of reasons for discontinuing HPN treatment in those patients labelled 
‘stopped HPN’ in Figure 3.4 
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Figure 3.6 
Kaplan Meier Survival Plot - All patients 
n=136 
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Figure 3.7 
Kaplan Meier Survival Plot 
Survival in those who died on HPN / those who were still receiving HPN at the censor 
date 
n=81 
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Figure 3.8 
Kaplan Meier Survival Plot - All patients 
Survival grouped by disease 
n=136 
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Figure 3.9 
Kaplan Meier Survival Plot – All Patients 
Survival grouped by age at initiation of HPN 
n=136 
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Figure 3.10 
Kaplan Meier Survival Plot – All Patients 
Grouped by time starting HPN 
n=136 
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Figure 3.11 
Kaplan Meier Survival Plot – All Patients 
Grouped by location. Dundee / Glasgow Royal Infirmary vs other centres 
n=136 
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Figure 3.12 
HPN dependence over time (all patients) 
n=136 
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Chapter 4 
Manganese levels in patients receiving HPN from a single Scottish 
tertiary referral centre 
4.1 Introduction 
Manganese (Mn) is considered an essential trace element which is required as an 
activator in many enzymatic reactions.   Patients receiving long-term parenteral 
nutrition are provided with Mn as part of a trace element solution which is added to 
their intravenous feed.   Differing preparations of multiple trace elements contain 
various amounts of Mn but further than this, refinement of daily dose is currently 
extremely difficult and crude.   Patients are prescribed HPN either with or without one 
of these this fixed dose supplements. 
 
Manganese absorption from the gastrointestinal tract is inversely correlated to dietary 
content.   Children and infants absorb more than adults and females appear to absorb 
more than males.   In the healthy adult, 5% of orally ingested Mn is absorbed and 
hypermanganesaemia is not a concern (Hardy, Hardy et al. 2008).   Elimination of 
manganese predominantly occurs through the hepatobiliary system and intestinal 
absorption is vital in manganese homeostasis.   In parenterally fed patients, this 
control is lost; Mn is 100% bioavailable resulting in a risk of hypermanganesaemia. 
 
The suspicion that cholestasis may play a role in hypermanganesemia originates from 
the knowledge that the liver is the primary organ involved in Mn uptake and 
excretion.   Cholestatic liver disease is a well recognized complication of total 
parenteral nutrition and with Mn undergoing biliary excretion, liver disease can lead 
to hypermanganesaemia.   In addition, some studies have suggested that Mn may be 
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causal in cholestasis, with reduction or withdrawal of Mn from feed correlating with a 
decrease in both bilirubin and aspartate aminotransferase (AST) and in one report 
experimentally infused manganese induced an intrahepatic cholestasis (Ayotte, Plaa 
1985).   In 1990, Mehta et al reported a woman who was receiving Mn-supplemented 
parenteral nutrition for 4 months presenting with a cholestatic jaundice and an 
extrapyramidal syndrome associated with high blood manganese levels.   Two years 
later, Ejima et al reported details of a man who received 23 months of HPN and 
developed no cholestatic jaundice, yet was found to have an accumulation of 
manganese in the basal ganglia giving rise to Parkinsonism (Mehta, Reilly 1990; 
Ejima, Imamura et al. 1992).   Following these observations, Fell et al examined 
children receiving parenteral nutrition and concluded that a complex relationship 
existed between hypermanganesaemia and cholestasis, with both abnormalities able to 
influence the existence of the other.   Levels of inflammatory markers have also been 
linked to levels of Mn in patients, with one study finding that Mn levels correlated 
with Erythrocyte Sedimentation Rate (ESR), and Tumour Necrosis Factor "  (TNF ") 
(Reimund, Dietemann et al. 2000). 
 
Cumulative Mn dose has also been suggested to be relevant in patients found to be 
hypermanganesemic.   Post mortem studies of cumulative Mn dosing showed high 
levels of manganese in patients’ tissues, especially those with liver and renal disease, 
and Howard et al (Howard, Ashley et al. 2007) suggest manganese, like copper, 
should be removed as an additive when liver-associated enzymes rise to twice normal. 
 
With the exception of experimentally induced cases, a single isolated clinical case of a 
short-bowel patient with Mn deficiency has been reported, where the deficiency was 
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successfully corrected with oral supplementation (Norose, Terai et al. 1992).   In 
contrast; long-term HPN patients are frequently reported as being 
hypermanganesaemic.   Excess Mn has led to neurological symptoms of 
hyperirritability and extrapyramidal disease in children.   These neurological 
symptoms correlated with increased signal intensity in the basal ganglia on magnetic 
resonance imaging (MRI) (Fell, Meadows et al. 1996; Reynolds, Blumsohn et al. 
1998).   MRI abnormalities slowly disappeared after manganese supplements were 
stopped.   Additionally, liver dysfunction improved once manganese supplementation 
was withdrawn from HPN (Fell, Meadows et al. 1996).   A study of post mortem 
manganese levels showed a cumulative effect of long term supplementation (Howard, 
Ashley et al. 2007).   Regular monitoring of patients receiving fixed doses of Mn over 
prolonged periods is recommended (Baxter 2009).   No satisfactory indicator of whole 
body Mn has to date been identified and neither plasma nor serum levels is felt to 
provide an accurate representation of levels.   As the majority of Mn is contained in 
red blood cells, Reynolds et al suggest that whole blood Mn concentrations are 
deemed the most reliable and reproducible monitoring parameter (Reynolds, 
Blumsohn et al. 1998).   In agreement with this, Hardy recently stated that whole-
blood levels are more accurate for monitoring and they correlate well with signal 
intensity of magnetic resonance imaging (Hardy 2009). 
 
Many reports have documented the existence of hypermanganesaemia in HPN 
patients (Wardle, Forbes et al. 1999; Reimund, Dietemann et al. 2000; Hardy, Hardy 
et al. 2008; Siepler, Nishikawa et al. 2003).   The Scottish HPN MCN provides the 
opportunity to examine the behaviour of Mn levels in chronic parenteral nutrition 
patients monitored closely at a tertiary referral nutrition centre.   As manganese 
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deficiency is virtually unknown in humans and there is growing evidence for toxicity 
if levels are high, any information regarding factors contributing to 
hypermanganesemia is valuable in understanding how to avoid excessive 
concentrations and identifying patients potentially at risk of toxicity as well as 
questioning whether it is necessary to add Mn to parenteral nutrition at all. 
 
This study aims to elucidate any relationship between WBMn levels and variables 
such as hepatic function, inflammation and cumulative Mn dose.   It also aims to 
determine whether WBMn level relates specifically and predictably to dose in the past 
7, 14, 21, 28, 56 and 84 days. 
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4.2 Methods 
All patients receiving HPN funded by the NHS in Scotland are known to the MCN 
through ongoing contact between the established centres and the Network Manager.   
This report includes all patients receiving long term HPN from Glasgow Royal 
Infirmary during 2007.   Long term is defined as greater than 12 months of treatment.   
All patients are monitored in accordance with the Scottish Home Parenteral Nutrition 
Managed Clinical Network (HPNMCN) recommended guidelines.   These advise that 
long-term HPN patients undergo regular micronutrient and trace element monitoring.   
Guidelines are based on expert opinion as, to date, little evidence base is available 
regarding frequency or content of HPN patient monitoring.   Currently, regular review 
infers three-monthly blood tests.   Blood was taken at clinic visits and sent to the 
Central Trace Element Laboratory which is based at Glasgow Royal Infirmary.  In 
addition, other blood tests were taken and sent for analysis as is part of any routine 
outpatient visit to the HPN clinic.   Together with other monitoring and clinical data, 
these results are entered in to a purpose built Microsoft Access database, which is 
completed prospectively by members of the nutrition team at the HPN MCN centre. 
 
All measurements of whole blood manganese were extracted from the database and 
missing or queried data resolved by one of the researchers (NH) contacting the local 
nutrition team and the central trace element laboratory at Glasgow Royal Infirmary.   
Other concurrent data collected included patient demographics, duration of HPN 
treatment, type and dose of trace element preparation prescribed and any changes in 
manganese prescription.   The two trace element preparations in use were Additrace 
which provided 1mg per dose and Decan which provided 0.04mg per dose.   
Additionally, where measured, ferritin (Ferr), alkaline phosphatase (ALP) and C 
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reactive protein (CRP) measurements corresponding to whole blood Mn (WBMn) 
levels were extracted. 
 
Individual patient whole blood manganese levels were extracted from the data set and 
average levels calculated for enforced times of 100, 500 and 1000 days post 
commencement of HPN.   Enforced times were generated by averaging all available 
levels of manganese and times of measurement for each individual patient into more 
comparable time periods i.e. all bloods taken within the first 100 days were averaged 
to give enforced time 100 and enforced Mn level 100 etc.   Similarly, alkaline 
phosphatase units/l, C reactive protein mg/litre and ferritin ng/ml levels were taken 
from the same time periods.   Cumulative Mn dose and consequently average Mn dose 
per day were also calculated for each patient.    
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4.3 Statistical Analysis 
Values for whole blood Manganese, ALP, CRP and ferritin were extracted from the 
Microsoft Access database as described above.   Correlations were tested using 
Matlab.   A Spearman correlation was performed, giving a correlation coefficient (R) 
and a p-value.   Initial testing showed a number of significant correlations between 
measured whole blood Mn and doses administered during the time-frame of interest.   
Correlations were repeated removing data points at which the dose on Mn during the 
time-frame of interest was zero, as these points were significantly skewing the data, 
producing significant associations from very few (occasionally 1) non-zero Mn dose 
data points. 
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4.4 Results 
4.4.1 Manganese levels within this study group 
In the first part of the study investigation concerned with manganese levels in 
individual patients and their relationships to manganese dose, liver function and 
markers of inflammation, a total of twelve patients had had sufficient time on HPN 
and sufficient clinic visits with blood tests to analyse their data.   Three patients were 
not included in this initial part of the study, two were not on HPN for an adequate 
duration (less than 1000 days) and one had had very few available blood test results to 
analyse.   With 12 patients and 3 time periods, a total of 36 Mn levels were possible 
(Table 4.1).   Three levels were not measured.   Eleven of the 12 (92%) patients 
recorded abnormally high Mn levels at least once, 5 patients at all three time points.   
Twenty-five of 33 (78%) Mn levels were abnormal and 13 (41%) of these were 
greater than twice normal levels (70-280nm/l).   Individual patient whole blood Mn 
levels relative to the normal range are shown in Figure 4.1. 
 
Table 4.1 Individual patient WBMn levels (nm/l) at three time points. 
Enforced 
Time 
(days) 
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8 Pt 9 Pt 10 
Pt 
11 
Pt 
12 
100 134 286 411 - 630 - 639 349 566 196 373 252 
500 322 207 1303 312 530 724 773 445 405 202 636 212 
1000 631 353 847 450 317 338 300 281 199 167 478 - 
 
4.4.2 Comparison of manganese level to other blood parameters 
Figures 4.2 – 4.4 show plots of whole blood Mn level v ALP, CRP, ferritin at time 
periods 100 days, 500 days and 1000 days. 
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In each case, reducing Mn dosage or stopping it completely resulted in a trend 
towards normal range Mn levels but overall there was no significant difference in 
WBMn levels over the three time periods. p = 0.236.   Neither CRP nor ferritin levels 
varied significantly over the time periods however ALP measurements were 
significantly different p = 0.013.    
 
4.4.3 Comparison of manganese levels with cumulative manganese dose 
Figure 4.5 shows whole blood Mn v cumulative Mn dose at the three time periods.   
An initial plot shows no obvious relationship between calculated cumulative Mn dose 
and WBMn level for any of the three enforced time periods. 
 
In the second part of the analysis, the population studied was all 15 patients who were 
receiving HPN under the care of the Glasgow Royal Infirmary nutrition team on 
31/12/2007.   Average age at the start of treatment was 59 years, with 5 male patients 
and 10 females.   The majority had a diagnosis of Crohns disease.   They had all been 
on HPN at least one year, with a median duration of 4.9 years of treatment (Table 
4.2). 
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Table 4.2 GRI HPN patient demographics. 
patient gender age at start diagnosis 
duration tx 
to date 
(yrs) 
Co-morbidities 
1 m 57.6 crohns disease 5.90 renal dysfunction 
2 f 56.5 crohns disease 6.52 none 
3 f 67.28 
short gut 
following surgery 
for benign 
condition 
5.83 liver dysfunction 
4 m 51.23 crohns disease 9.76 renal dysfunction 
5 f 56.63 fistula following surgery 6.03 none 
6 m 52.54 crohns disease 7.13 renal dysfunction 
7 f 49.8 crohns disease 9.92 osteoporosis 
8 m 15.93 crohns disease 5.33 none 
9 f 54.45 motility disorder 3.38 
liver dysfunction, 
protein losing 
enteropathy 
10 f 41.63 crohns disease 15.01 renal dysfunction 
11 f 62.87 ischaemia 3.74 none 
12 f 60.84 ischaemia 2.62 none 
13 f 30.26 crohns disease 2.50 none 
14 m 40.56 sclerosing peritonitis 2.47 renal dysfunction 
15 f 54.61 malignancy 1.71 none 
 
4.4.4 Cumulative manganese dose 
No relationship was demonstrated between cumulative dose and WBMn.   When Mn 
levels are plotted using symbol coding to identify each patient separately, no 
relationship is found within either intra or inter patient data (Figure 4.6). 
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Table 4.3 Correlation coefficients and p values for each patient between cumulative 
Mn dose and WBMn level 
patient R values P values 
1  0.2741 0.2561 
2 -0.399 0.0814 
3 -0.5672 0.0544 
4 -0.0947 0.7271 
5 -0.633 0.0085 
6 -0.1371 0.6402 
7 -0.4877 0.0553 
8 -0.2991 0.4718 
9 -0.6596 0.0532 
10 -0.3216 0.3649 
11 -0.2275 0.588 
12 -0.9801 0.0034 
13 -0.2056 0.5687 
14  0.2369 0.609 
15 -0.5702 0.3156 
 
Correlation between manganese dose in the previous 7, 14, 21, 28, 56 and 84 days and 
whole blood Mn level was investigated.   Data was skewed by the presence of large 
numbers of data points at which a blood Mn level was measured, but there had been 
no Mn dosing during the prior time period of interest.   P values resulting from 
correlation testing including these zero values is shown in Table 4.4.   The results of 
correlation testing following the removal of these zero-value data points are shown in 
Table 4.5. 
 
  
126 
126 
Table 4.4 p values following correlation between Mn dose in time period specified 
and measured Mn level 
Patient 7 days 14 days 21 days 28 days 56 days 84 days 
1 0.037 0.034 0.033 0.033 0.02 0.108 
2 0.009 0.008 0.008 0.006 0.004 0.002 
3 0.006 0.006 0.006 0.006 0.002 0.002 
4 0.001 0.001 0.001 0.001 0.001 0.001 
5 0.001 0.001 0.001 0.001 0.001 0.001 
6 0.394 0.414 0.421 0.424 0.448 0.536 
7 0.192 0.179 0.237 0.367 0.61 0.698 
8 0.315 0.323 0.326 0.327 0.329 0.331 
9 0.001 0.001 0.001 0.001 0.001 0.001 
10 0.016 0.016 0.016 0.017 0.029 0.037 
11 0.017 0.017 0.017 0.017 0.017 0.017 
12 0.431 0.637 0.816 0.795 0.248 0.246 
13 0.146 0.125 0.125 0.125 0.031 0.018 
14 0.001 0.001 0.001 0.008 0.001 0.002 
15 no value no value 0.961 0.961 0.961 0.961 
 
Table 4.5 p values following correlation between Mn dose in time period specified 
and measured Mn level, following removal of data points in which the Mn dose 
during the specified time period was zero. 
Patient 7 days 14 days 21 days 28 days 56 days 84 days 
1 no value no value no value no value no value 0.756 
2 0.82 0.814 0.813 0.212 0.084 0.027 
3 no value no value no value no value 0.473 0.473 
4 no value no value no value no value no value no value 
5 0.12 0.12 0.12 0.12 0.12 0.12 
6 0.46 0.46 0.46 0.46 0.753 0.622 
7 0.192 0.179 0.237 0.367 0.61 0.698 
8 0.315 0.323 0.326 0.327 0.329 0.331 
9 no value no value no value no value no value no value 
10 no value no value no value 0.211 0.211 0.211 
11 no value no value no value no value no value no value 
12 no value no value no value no value no value no value 
13 no value no value no value no value no value no value 
14 no value no value no value no value no value no value 
15 no value no value no value no value no value no value 
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4.5 Discussion 
Numbers are small in this study of a single tertiary centre and this fact must be 
acknowledged prior to interpretation and discussion of results.   There is undoubtedly 
a high incidence of high WBMn levels amongst our patients.   In individual cases, this 
is responsive to a decrease in Mn dosage or the omission of Mn supplementation from 
intravenous feed.   Although levels fell in response to dose alteration, they very often 
remained high months later at the next three monthly micronutrient screening.   
Perhaps Mn continues to be released from high level tissue stores for an unknown 
duration following dose adjustment. 
 
The high manganese levels cannot be adequately explained by changes in 
inflammatory markers or liver dysfunction as there was no significant correlation with 
markers of either.   The lack of relationship between cumulative dose and WBMn in 
the first part of this study is maintained in the second part where it is examined more 
closely by calculating correlation coefficients for each patient.   The results show a 
lack of correlation between these variables.   In retrospect, given that each analysis 
point includes data from the preceding analysis point, it is questionable whether this 
section of the study concerning cumulative dose is statistically valid. 
 
Manganese dose in the previous 7, 14, 21, 28, 56 and 84 days were examined with 
respect to WBMn levels.   It was postulated that one of these time periods may show a 
positive relationship to WBMn level and that it would be clinically useful to be able to 
state that the dose in the preceding x days is most relevant and predictive of Mn level.   
This data was skewed by the presence of large numbers of data points at which a 
blood Mn level was measured, but there had been no Mn dosing during the prior time 
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period of interest.   Correlation testing including these zero values gave a high number 
of significant positive correlations, even in cases where there were very few non-zero 
values (Table 4.3).   Correlation testing following the removal of these data points at 
which no Mn had been given during the period of interest showed only a single 
significant association at 84 days in a single patient.   It can therefore be concluded 
that there is no clinically useful correlation between Mn dosing and Mn level during 
the time frames investigated.   It may also be questioned whether it is valid to draw 
conclusions from this analysis, as the Mn dose at each time period also includes the 
doses from previously analysed shorter time periods and is therefore not an 
independent variable.   Additionally, the latter patients whose Mn levels were 
monitored with respect to their cumulative and 7, 14, 21, 28, 56 and 84 day doses had 
few monitoring dates, each having been receiving HPN for relatively short amounts of 
time. 
 
In this study manganese levels did not correlate with either cumulative dose of Mn, 
recent dose of Mn or cholestasis.   This is in agreement with previous studies (Wardle, 
Forbes et al. 1999), and suggests that factors other than manganese excretion and 
manganese dosage may be responsible for blood levels of the trace element.   Oral 
intake in this study was not quantified but it is informally known that most patients 
involved in this study take some degree of enteral nutrition.   It is possible that oral 
plus parenteral manganese provision may have some bearing on the high WBMn 
levels recorded.   Wardle et al (Wardle, Forbes et al. 1999) and Siepler et al (Siepler, 
Nishikawa et al. 2003) agree that this is a valid possibility yet a difficult factor to 
quantify.   Tea and leafy vegetables are rich sources of manganese (Reynolds, 
Blumsohn et al. 1998) and in this current study no attempt to document the specifics 
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of oral intake was made.   This may have been a useful addition to the data collected 
and should certainly be considered for future work. 
 
Apart from inappropriately high dosages, Mn contamination of intravenous products 
is a concern.   For more than 20 years studies from the United States have shown that 
PN solutions without Mn supplementation can contain 5–38 ng/L, especially from 
calcium gluconate, magnesium sulphate, or potassium chloride (Pluhator-Merton, 
Fedorak et al. 1999).!!!The reports of Mn contamination have been so widespread over 
the years that there is no doubt there is a problem that needs to be addressed by 
manufacturers (Hardy 2009).   Manganese is also present in the needles and tubing 
used to acquire and process blood samples and this, together with the unreliability of 
dosage secondary to contamination from what is officially manganese-free parenteral 
nutrition makes it even more difficult to ensure consistent intake and support a 
cautious approach to prescribing this metal. 
 
In previous studies, hypermanganesemia has correlated with abnormal MRI scans in 
the patients concerned, brain Mn storage being very slowly cleared from cerebral 
mitochondria even when parenteral Mn supplementation is discontinued (Alves, 
Thiebot et al. 1997; Mirowitz, Westrich et al. 1991).   However, none of the patients 
scanned in these studies exhibited clinical signs of extrapyramidal disease or 
psychosis (Bertinet, Tinivella et al. 2000).   It is not disputed that a method of 
monitoring to prevent Mn accumulation is highly necessary in HPN patients.   
However, routine MRI is not a feasible option and the search for an accurate and 
reliable marker of Mn build up continues. 
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In conclusion, patients in the current study have demonstrable hypermanganesemia, in 
line with HPN patients from many previous studies.   This study aimed to address this 
observation, and confirm or refute some possible causes.   However, from the outset it 
was noticeable that Mn concentrations differed wildly between patients and no clear 
dose-response was evident.   Later in the study and also concerning was the plan to 
draw conclusions from measurements which contained subsets of the same data with 
respect to dose in the past 7, 14, 21, 28, 56 and 84 days; each longer period also 
encompassing the shorter periods analysed before. 
 
What can be concluded is that no association was found between whole blood Mn 
level and either alkaline phosphatase, C reactive protein or ferritin at any of the three 
enforced time periods.   In addition, in both parts of the study, and despite the various 
forms of analysis used, no correlation was demonstrated between cumulative Mn dose 
and WBMn level.   Finally, no correlation was demonstrated between dose over time 
periods examined and WBMn level.   Other possible causes of Mn accumulation 
which have previously been raised and have not to date been excluded include dietary 
intake and Mn contamination of intravenous nutrition.   It is still possible that either of 
these variables may be clinically relevant or in fact the result is multifactorial and 
many of the above mentioned factors play some role in hypermanganesemia.   One 
last possibility is that we have not identified the most relevant marker of tissue Mn 
and this may be key to elucidating a more clinically useful relationship.    
 
Regarding Mn supplementation in HPN patients; with increasing data showing high 
levels of WBMn and the scarcity of Mn deficiency, together with the difficulties 
experienced in monitoring Mn experienced to date, it may be relevant and prudent to 
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consider the possibility of discontinuing the routine use of manganese 
supplementation in patients requiring long term parenteral feeding. 
  
132 
132 
 
Figure 4.1 
Individual patient whole blood Mn levels related to normal range. 
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Figure 4.2 
Whole blood Manganese vs ALP, CRP and Ferritin at 100 days 
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Figure 4.3 
Whole blood Manganese vs ALP, CRP and Ferritin at 500 days 
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Figure 4.4 
Whole blood Manganese vs ALP, CRP and Ferritin at 1000 days 
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Figure 4.5 
Whole blood Mn v cumulative Mn dose at the three time periods (100, 500 and 1000 
days) 
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Figure 4.6 
The relationship between measured whole blood Mn and log cumulative Mn dose.   
All data points for all patients.   Individuals differentiated by colour. 
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Conclusions 
Home Parenteral Nutrition remains the core treatment for patients with intestinal 
failure.   In Scotland, the HPN Managed Clinical Network plays a crucial role in 
ensuring the provision of the therapy to all appropriate patients.   It also facilitates 
local monitoring of patients and makes possible audit and research projects aiming to 
further enhance understanding and improve treatment with respect to chronic 
intestinal failure. 
 
In chapter one, the monitoring of Scottish HPN patients was investigated and 
compared with the recommended standards for frequency and content of review.   
Only one third of patients consistently met the set standard of review frequency yet no 
relationship was found between other patients reviewed less often and any increase in 
frequency of complication requiring hospitalisation.   This finding may go some way 
to providing support for reduced frequency in review of this type of patient.   To 
qualify this, and notably, patients seen more often in this study had a few more 
recorded HPN related complications, inferring that there may be some informal 
decisions to more closely follow those with stormier courses of treatment.   
Formalising this approach may of course benefit the already overstretched NHS both 
financially and in clinical workload. 
 
Content of review appointments was on the whole encouraging.   Improvements can 
and should be made in simple areas such as weight measurement, a crucial parameter 
in nutrition patients.   Over and above this, the skill mix of the nutrition team varies 
between centres and this is evident from biochemical and anthropometric data.   This 
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is a more difficult problem to standardise but education of team members and a 
written proforma to guide a clinic review may be of some benefit. 
 
Chapters 2 and 3 again benefit from the data of an entire geographical population.   
Survival and HPN dependence statistics were acquired for Scottish HPN patients and 
were broadly comparable with those of a tertiary UK referral centre for Intestinal 
Failure.   This is encouraging for the MCN who strive to provide the same level of 
care as the main IF centres over a wide area, with multiple teams and in numerous 
distant settings.   Patient deaths were in the main disease related, and diagnosis was 
significant in predicting outcome in line with other recent studies.   HPN dependence 
was acceptable and in fact less at five years than in the tertiary centre, probably 
reflecting a different mix of pathology and perhaps a smaller centre approach to the 
constant consideration of patient suitability for weaning.   Anecdotally, some centres 
have more of a surgical slant to management of IF than others, and comparison of our 
Scottish data to this type of institution would prove interesting.   Heartening was the 
comparison of two larger HPN centres to the rest of the Scottish HPN bases and the 
demonstration of no difference in outcome, strengthening the success of the Network.   
Recommendations from this study would include improvement of the database itself, 
to promote accuracy and detail in documentation of complication and mortality data. 
 
The last chapter concerns manganese analysis in the Scottish HPN population.   It is 
true to say that, as in many other reported studies, our patients are frequently 
hypermanganesemic, yet remain clinically asymptomatic and with to date, little 
demonstrable relationship between manganese prescription and measured whole 
blood Mn level.   From the outset, and with initial crude analysis of results, no 
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correlation was evident between these two variables.   Some patients received Mn 
doses orders of magnitude greater than others and had normal Mn measurements, with 
other receiving minimal doses and still achieving hypermanganesemic states.   In 
retrospect, perhaps these results should have raised questions regarding the usefulness 
of pursuing this line of investigation.   Formal analysis of cumulative Mn dose versus 
Mn level again showed no correlation and validity of the figures is debatable when 
each dose is deemed not to be independent, being influenced by all previous doses.   
No explanation for high Mn levels was found in other blood parameters, and it is 
probable that a highly complex relationship exists between multiple influences to 
produce hypermanganesemia.   Uncertainty exists as to the measurable form in which 
Mn most accurately behaves as a biomarker of the whole body content.   Whole 
blood, plasma and red cell Mn have all been suggested to represent tissue levels.   
However, to date, and with such a definite lack of relationship between dose and 
response so far, perhaps obtaining tissue levels of HPN patients at opportune times 
e.g. operative intervention may further elucidate the behaviour of Mn dosing at tissue 
level and provide some guidance to its influences.   Lastly, in the knowledge that 
clinical hypomanganesemia is almost unknown and dietary and contamination routes 
can both provide small quantities of the trace element, perhaps the next step in 
addressing this nutritional dilemma is to examine levels in HPN patients receiving no 
formal manganese prescription with the hypothesis that its addition may be 
superfluous.  
The current study has examined a small amount of the data potentially available from 
the MCN.   This data provides a unique resource in terms of the inclusion of the 
generality of HPN patients rather than the selected population of a tertiary referral 
centre.   Future work and further potential studies would include a closer look at HPN 
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feed prescriptions, the behaviour of liver enzymes in HPN patients, analysis of the 
MCN anthropometric data and detailed investigation of other trace elements recorded 
in the Scottish HPN MCN which can be easily accessed through their central 
processing at Glasgow Royal Infirmary. 
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